HIDROGEL E LIGANTE-FÁRMACO

Ligands with a geminal substituted carbon structure address the issue of unwanted aza-Michael addition, enhancing stability and prolonging drug release in conjugates, as shown by effective drug delivery in animal models.

BR122026021287A2Pending Publication Date: 2026-11-10PROLYNX LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR122026021287
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-04-05
Filing Date
2020-04-03
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing β-eliminative ligands used for drug conjugation suffer from unwanted aza-Michael addition reactions, particularly at physiological pH, leading to undesirable side reactions and reduced efficacy.

Method used

Development of ligands with a geminal substituted carbon adjacent to the leaving oxygen, which suppresses nucleophilic addition and stabilizes the conjugate, using a formula (I) structure to enhance stability and control drug release.

Benefits of technology

The new ligands effectively suppress aza-Michael addition, maintaining conjugate stability and enabling prolonged drug release, as demonstrated by sustained drug delivery in animal models.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art

Description

1 / 71 Hydrogel and Binder - Drug (Split Order BR 11 2021 020023 1) CROSS-REFERENCE TO RELATED REQUESTS

[001] This application claims priority for U.S. Provisional Application No. 62 / 830,280, filed April 5, 2019, the contents of which are incorporated herein by reference in their entirety. EMBEDDING BY SEQUENCE LISTING REFERENCE

[002] This application is being filed together with a sequence listing in electronic format. The Sequence Listing is submitted as a file titled 670572002140SeqList.txt, created on April 3, 2020, which is 2,112 bytes in size. The information in the electronic format of the Sequence Listing is incorporated by reference in its entirety. FIELD

[003] This description generally refers to β-eliminative ligands suitable for the conjugation of small molecules, peptides, oligonucleotides, and proteins and compounds comprising the ligands. FUNDAMENTALS

[004] Drug molecules are covalently linked to macromolecular carriers in order to enhance pharmaceutical properties such as half-life, stability, solubility, tolerability, and safety. US Patents 8,680,315, 8,754,190, and 9,649,385 describe conjugated drug systems having β-eliminative ligands, which allow drug release through a rate-controlled beta-elimination mechanism. However, along with the released drug or broken crosslinking, the β-elimination process generates a ligand residue linked to the macromolecular carrier comprising an alkenyl group that can be activated for nucleophilic addition. As shown in Figure 1, potential nucleophiles for this addition under conditions Petition 870260086668, dated 08 / 25 / 2026, page 12 / 110 2 / 71 physiological reactions include thiols and amines, for example, those present in significant quantities in proteins or, more likely, amines released from the rupture of a crosslink in a hydrogel. Although amines are expected to be protonated and thus non-reactive at physiological pH, it has been unexpectedly found that such aza-Michael addition occurs at least in an in vitro setting. Previously described ligands (i.e., US Patents 8,680,315 and 8,754,190) provide a means of alleviating this unwanted reaction by adding an alkyl group to the carbon having the leaving oxygen (equivalent to the R5 group in formula (I) of US Patent 8,680,315), as shown in Figure 2. There is a need for improved ligands that can suppress unwanted aza-Michael addition more effectively. BRIEF SUMMARY

[005] In one aspect, a ligand of formula (I) is provided, R1I R4HC---R2O I III Z---(CHJn----Ç---C---O---CX R4H(I), where n, R1, R2, R4, X, and Z are as described herein. In some embodiments, the ligand is a β-eliminative ligand. In some embodiments, the β-eliminative ligand is appropriate for small molecule, peptide, and therapeutic protein conjugation.

[006] In another aspect, a drug-ligand of formula (II) is provided, R1I R4HCR Z---(CH^n----C---C---O---C---YD R4H(II), where n, R1, R2, R4, Y, Z, and D are as described here. In Petition 870260086668, dated 08 / 25 / 2026, p. 13 / 110 3 / 71 In some embodiments, the drug-ligand of formula (II) is prepared by combining the ligand of formula (I) with a drug such as a small molecule, a peptide or a therapeutic protein.

[007] In yet another aspect, a conjugate of formula (III) is provided, Γr1-| I R4HC---R2O I III M—|-Z·---(CH,)n----C---C---O---C---YD where n, q, R1, R2, R4, M, Y, Z*, and D are as described herein. In some embodiments, the conjugate of formula (III) is a drug conjugate D releasably linked to a macromolecular carrier M via a ligand of formula (I).

[008] In yet another aspect, a hydrogel of formula (IV) is provided, where n, r, R1, R2, R4, W, Z*, P1, and P2 are as described herein. In some embodiments, the compound of formula (IV) is a degradable crosslinked hydrogel. In some embodiments, the degradable crosslinked hydrogel comprises the residue of a binder of formula (I). In yet another aspect, methods are provided for preparing the compounds of formulas (I), (II), (III), and (IV), and methods for their use. In another aspect, pharmaceutical compositions having a conjugate of formula (III) or a hydrogel of formula (IV) are provided. Petition 870260086668, dated 08 / 25 / 2026, p. 14 / 110 4 / 71 BRIEF DESCRIPTION OF THE DRAWINGS

[009] Figure 1 illustrates the cleavage of a carbamate ligand described in US Patent 9,649,385 into a conjugate. The intact conjugate 1 undergoes a pH-dependent beta-elimination reaction leading to ligand cleavage and formation of remnant ligand 2 along with free amine 3. These products can undergo a subsequent reversible aza-Michael reaction to form a relatively stable readdition adduct 4. When R is a drug or prodrug containing amine, the ligand is a drug-releasing ligand. When R is a second PEG prepolymer, the ligand is part of a crosslinker in a PEG hydrogel.

[010] Figure 2 illustrates the cleavage of a carbamate ligand described in US Patent 9,649,385 into a conjugate, wherein both R5 groups are alkyl. The steric hindrance by the alkyl groups in R5 is expected to retard the readdition process.

[011] Figure 3 illustrates the cleavage of a γdisubstituted carbamate ligand described here into a conjugate.

[012] Figure 4 shows the rate of aza-Michael addition of glycine to vinyl sulfone ligands at various pH indices. Prism plot of glycine adduct concentration (mM) versus time (for the ligands Std (standard), β-Me, and gem diMe: A) pH 7.4, 1.0 M glycine; B) pH 8.4, 1.0 M glycine; C) pH 9.5, 0.1 M glycine. Tabulated data from each experiment including kf, kr, and Keq were calculated as described in the Methods section.

[013] Figure 5 shows the retro-aza-Michael elimination rate of glycine from β-N-glycyl methyl sulfones. A) Scheme of the retro-aza-Michael reaction for each ligand. B) Prism plot of adduct concentration (pM) versus time (h). Standard ligand, kobs = 0.0030 h-1; β-Me ligand, kobs = 0.0050 h-1; gem diMe ligand, kobs = 0.0060 h-1. For each ligand, the calculated [Gly-adduct]equil < 1 pM.

[014] Figure 6 shows an illustrative structure of a hydrogel. Petition 870260086668, dated 08 / 25 / 2026, page 15 / 110 5 / 71 comprising formula cross-links (IV).

[015] Figure 7 shows an illustrative structure of a drug-releasing hydrogel comprising crosslinks of formula (IV). A drug ligand (DL) of formula (II) is attached to the hydrogel via reactive group B.

[016] Figure 8 shows the plasma concentration of exenatide[N28Q] released from the exenatide-releasing hydrogel microsphere conjugate of example 18. Rats (n=3) were subcutaneously injected with a suspension of the conjugate comprising 9.2 μmol / kg of exenatide[N28Q] on day 0. Plasma samples were obtained and analyzed by LC / MS. The conjugate provided continuous exposure to exenatide[N28Q] for at least 84 days after injection, showing a release t1 / 2 of 750 hours (31 days).

[017] Figure 9 shows blood glucose measured in STZ-induced diabetic mice treated with the insulin lispro hydrogel microsphere conjugate of Example 17. Mice were treated with streptozotocin to induce diabetes, then injected subcutaneously with a suspension of the conjugate comprising either 1.2 μmol / kg (low dose, squares) or 4.8 μmol / kg (high dose, triangles) of insulin lispro on days 0 and 7. The vehicle control (circles) consisted of peptide-free microspheres. Blood samples were taken and analyzed for blood glucose. The low dose suppressed blood glucose for 1 day, while the high dose suppressed blood glucose for 5 days after injection. The effects were repeated after the second dose.

[018] Figure 10 shows the body weight measured in STZ-induced diabetic mice treated with the insulin lispro-releasing hydrogel microsphere conjugate of example 17. Mice were treated with streptozotocin to induce diabetes, then injected sc with a suspension of the conjugate comprising either 1.2 μmol / kg (low dose, squares) or 4.8 μmol / kg (high dose, triangles) of insulin lispro on days 0 and Petition 870260086668, dated 08 / 25 / 2026, page 16 / 110 6 / 71 7. The vehicle control (circles) consisted of microspheres containing no peptides. Both low and high doses of the conjugate maintained the animal's body weight, while the vehicle control lost 17% over 6 days. DETAILED DESCRIPTION

[019] Compared with the previously described β-eliminative ligands, it has been found that the undesired aza-Michael addition can be suppressed much more effectively by the ligands described herein, which incorporate a geminal substituted carbon adjacent to the carbon having the leaving oxygen, i.e., on the gamma-carbon, as shown in Figure 3. The resulting ligands of formula (I) described herein provide conjugates in which the rate of nucleophilic addition to the remaining ligand is greatly suppressed, and the resulting equilibrium constant is correspondingly very low. Definitions

[020] For use herein, unless clearly indicated otherwise, the use of the terms a, an and similar terms refers to one or more.

[021] As used herein, and unless otherwise specified, the term about, when used in connection with a value, contemplates a value within 15%, within 10%, within 5%, within 4%, within 3%, within 2%, within 1%, or within 0.5% of the value.

[022] The term alkyl includes linear, branched, or cyclic saturated hydrocarbon groups of 1-20, 1-12, 18, 1-6, or 1-4 carbon atoms. In some embodiments, an alkyl is linear or branched. Examples of linear or branched alkyl groups include, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, indecyl, and the like. In some embodiments, an alkyl is cyclic. Examples of cyclic alkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, Petition 870260086668, dated 08 / 25 / 2026, p. 17 / 110 7 / 71 cyclopentadienyl, cyclohexyl and similar compounds.

[023] The term alkoxy includes alkyl groups attached to oxygen, including methoxy, ethoxy, isopropoxy, cyclopropoxy, cyclobutoxy, and the like.

[024] The term “alkenyl” includes non-aromatic unsaturated hydrocarbons with carbon-carbon double bonds and 2-20, 212, 2-8, 2-6, or 2-4 carbon atoms.

[025] The term “alkynyl” includes non-aromatic unsaturated hydrocarbons with carbon-carbon triple bonds and 2-20, 212, 2-8, 2-6, or 2-4 carbon atoms.

[026] The term “aryl” includes aromatic hydrocarbon groups of 6-18 carbons, preferably 6-10 carbons, including groups such as phenyl, naphthyl and anthracenyl. The term “heteroaryl” includes aromatic rings comprising 3-15 carbons containing at least one N, O or S atom, preferably 3-7 carbons containing at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, indenyl and the like.

[027] In some examples, alkenyl, alkynyl, aryl, or heteroaryl moieties may be coupled to the rest of the molecule via an alkyl linkage. Under these circumstances, the substituent will be referred to as alkenylalkyl, alkynylalkyl, arylalkyl, or heteroarylalkyl, indicating that an alkylene moiety is between the alkenyl, alkynyl, aryl, or heteroaryl moiety and the molecule to which the alkenyl, alkynyl, aryl, or heteroaryl moiety is coupled.

[028] The term halogen” or halo” includes bromine, fluorine, chlorine and iodine.

[029] The term heterocyclic ring or heterocyclyl refers to a 3-15 membered aromatic or non-aromatic ring comprising at least one N, O, or S atom. Examples include, without limitation, piperidinyl, piperazinyl, tetrahydropyranyl, Petition 870260086668, dated 08 / 25 / 2026, p. 18 / 110 8 / 71 pyrrolidine, and tetrahydrofuranyl, as well as the exemplary groups provided for the term heteroaryl above. In some embodiments, a heterocyclic or heterocyclyl ring is non-aromatic. In some embodiments, a heterocyclic or heterocyclyl ring is aromatic.

[030] The term macromolecule refers to a molecule or residue of a molecule having a molecular weight between 5,000 and 1,000,000 Daltons, preferably between 10,000 and 500,000 Daltons, and more preferably between 10,000 and 250,000 Daltons. Examples of macromolecules include, without limitation, proteins including antibodies, antibody fragments, and enzymes; polypeptides including poly(amino acids) such as poly(lysine) and poly(valine) and mixed-sequence polypeptides; synthetic polymers including poly(ethylene glycol) (PEG), poly(ethylene oxide) (PEO), poly(ethylene imine) (PEI), and copolymers thereof; and polysaccharides such as dextrans. In some embodiments, the macromolecules comprise at least one functional group suitable for conjugation, either natively or after chemical transformation, such as an amine, carboxylic acid, alcohol, thiol, alcine, azide, or maleimide group as described above. In certain embodiments of the invention, the macromolecule is a polyethylene glycol.Polyethylene glycol can be linear or branched, with one end terminated with a functional group suitable for conjugation and the other end or ends terminated by a capping group (e.g., methyl), or it can comprise multiple arms, each arm terminating in a functional group suitable for conjugation. In preferred embodiments of the invention, polyethylene glycol is a linear, branched, or multi-armed polymer having an average molecular weight between 20,000 and 200,000 Daltons, preferably between 20,000 and 100,000 Daltons, and most preferably approximately 40,000 Daltons. Examples of such polyethylene glycols are known in the art and commercially. Petition 870260086668, dated 08 / 25 / 2026, page 19 / 110 9 / 71 available, for example, from NOF Corporation (Tokyo, Japan).

[031] The terms protein and peptide are used interchangeably regardless of chain length, and these terms additionally include pseudopeptides comprising linkages other than amide linkages, such as CH2NH2 linkages, as well as peptidomimetics.

[032] The terms nucleic acid and oligonucleotide are also used interchangeably regardless of chain length. Nucleic acids or oligonucleotides may be single-stranded or duplex, or may be DNA, RNA, or modified forms thereof with altered linkages, such as phosphodiesters, phosphoramidates, and the like. For both proteins and nucleic acids useful as drugs in the invention, these terms also include those with side chains not found in nature in the case of proteins, as well as pseudopeptide linkages and bases not found in nature in the case of nucleic acids, as well as main chain variants such as peptide nucleic acids.

[033] The term small molecule in the context of drugs is a well-understood term in the art and is intended to include compounds other than proteins and nucleic acids that are either synthesized or isolated from nature and generally do not resemble proteins or nucleic acids. Typically, they have molecular weights <1,000, although there is no recognized specific cutoff. However, the term is well understood in the fields of pharmacology and medicine.

[034] Optionally substituted, unless otherwise specified, means that a group may be unsubstituted or substituted by one or more (e.g., 1, 2, 3, 4, or 5) of the substituents, which may be the same or different. Examples of substituents include, without limitation, alkyl, alkenyl, alkynyl, halogen, -CN, -ORaa, -SRaa, -NRaaRbb, -NO2, -C=NH(ORaa), -C(O)Raa Petition 870260086668, dated 08 / 25 / 2026, p. 20 / 110 10 / 71 , -OC(O)Raa, -C(O)ORaa, -C (0) NRaaRbb, -OC (0) NRaaRbb, -NRaaC (0) Rbb, NRaaC (0) 0Rbb, -S(O)Raa, -S (0)2Raa, -NRaaS (0) Rbb, -C (0) NRaaS (0) Rbb, -NRaaS (0) 2Rbb, -C (0) NRaaS (0) 2Rbb, -S (0)NRaaRbb, -S (0)2NRaaRbb, -P (0) (0Raa) (0Rbb) , heterocyclyl, heteroaryl, or aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, and aryl are each independently optionally substituted by Rcc, wherein Raae Rbb are each independently H, alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl, or aryl, or Raae Rbbsão are taken together with the nitrogen atom to which they attach to form a heterocyclyl, which is optionally substituted by alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, or -CN, and in which: each Rcc is independently alkyl, alkenyl, alkynyl, halogen, heterocyclyl, heteroaryl, aryl, -CN, or -N02.

[035] Although typically the active form of the drug is released directly from the conjugates of the invention, in some cases it is possible to release the active drug in the form of a prodrug thereof. Binder

[036] In one aspect, a ligand of formula (D , is provided here R1 R4HC---R2O Z---(CHJn----C---C---O---C---X II R4H (I) , where: n is an integer from 0 to 6; R1 and R2 are independently an electron-withdrawing group, alkyl, or H, and wherein at least one of R1 and R2 is an electron-withdrawing group; Is each R4 independently C1-C3 alkyl or are both R4s Petition 870260086668, dated 08 / 25 / 2026, p. 21 / 110 11 / 71 taken together with the carbon atom to which they attach to form a 3-6 membered ring; X is an outgoing group; and Z is a functional group used to connect the ligand to a macromolecular carrier.

[037] In some embodiments of a ligand of formula (I), n = 1-6, R1 and R2 are independently electron-withdrawing groups, alkyl, or H, and wherein at least one of R1 and R2 is an electron-withdrawing group; each R4 is independently C1-C3 alkyl or taken together can form a 3-6 membered ring; X is halogen, active ester such as N-succinimidyloxy, nitrophenoxy, or penta-halophenoxy, or imidazolyl, triazolyl, tetrazolyl, or N(R6)CH2Cl wherein R6 is optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and Z is a functional group to connect the ligand to a macromolecular carrier.

[038] In some embodiments, the electron-withdrawing group of R1e R2e - CN; - NO2; optionally replaced aril; optionally replaced heteroaryl; optionally substituted alkenyl; optionally substituted alkynyl; - COR3, -SOR3, or -SO2R3, wherein R3 is H, optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -OR8 or -NR82, wherein each R8 is independently H or optionally substituted alkyl or both R8 groups are taken together with the nitrogen to which they are attached to form a heterocyclic ring; or Petition 870260086668, dated 08 / 25 / 2026, page 22 / 110 12 / 71 SR9, wherein R9 is optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl.

[039] In some embodiments, the electron-withdrawing group of R1e R2e is -CN. In some embodiments, the electron-withdrawing group of R1e R2e is -NO2. In some embodiments, the electron-withdrawing group of R1e R2e is an optionally substituted aryl containing 6-10 carbons. For example, in some embodiments, the electron-withdrawing group of R1e R2e is an optionally substituted phenyl, naphthyl, or anthracenyl. In some embodiments, the electron-withdrawing group of R1 and R2 is an optionally substituted heteroaryl group comprising 3-7 carbons and containing at least one N, O, or S atom. For example, in some embodiments, the electron-withdrawing group of R1 and R2 is an optionally substituted pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, or indenyl group. In some embodiments, the electron-withdrawing group of R1 and R2 is an optionally substituted alkenyl group containing 2-20 carbon atoms.In some embodiments, the electron-withdrawing group of R1 and R2 is optionally substituted alkynyl containing 2-20 carbon atoms. In some embodiments, the electron-withdrawing group of R1 and R2 is -COR3, -SOR3, or -SO2R3, wherein R3 is H, optionally substituted alkyl containing 1-20 carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -OR8 or -NR82, wherein each R8 is independently H or optionally substituted alkyl containing 1-20 carbon atoms, or both R8 groups are taken together with the nitrogen to which they are attached to form a heterocyclic ring. In some embodiments, the electron-withdrawing group of R1 and R2 is -SR9, wherein R9 is optionally substituted alkyl containing 1. Petition 870260086668, dated 08 / 25 / 2026, p. 23 / 110 13 / 71 carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl.

[040] In some embodiments of a ligand of formula (I), at least one of R1 and R2 is -CN, -SOR3 or -SO2R3. In some embodiments, at least one of R1 and R2 is -CN or -SO2R3. In some embodiments, at least one of R1 and R2 is -CN or -SO2R3, wherein R3 is optionally substituted alkyl, optionally substituted aryl or -NR82. In some embodiments, at least one of R1 and R2 is -CN, -SO2N(CH3)2, -SO2CH3, -SO2Ph, -SO2PhCl, SO2N(CH2CH2)2O, -SO2CH(CH3)2, -SO2N(CH3)(CH2CH3), or SO2N(CH2CH2OCH3)2.

[041] In some embodiments of a ligand of formula (I), each R4 is independently C1-C3 alkyl. In some embodiments, both R4s are methyl.

[042] In some embodiments of a formula (I) ligand, n is an integer from 1 to 6. In some embodiments, n is an integer from 1 to 3. In some embodiments, n is an integer from 0 to 3. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3.

[043] In some embodiments of a ligand of formula (I), X is a halogen, an active ester (for example, N-succinimidyloxy, nitrophenoxy, or penta-halophenoxy), an optionally substituted heteroaryl (for example, imidazolyl, triazolyl, or tetrazolyl), or -N(R6)CH2Cl wherein R6 is an optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, X is a halogen. In some embodiments, X is an active ester such as succinimidyloxy. In some embodiments, X is -N(R6)CH2Cl, wherein R6 is an optionally substituted aryl.

[044] For a ligand of formula (I), Z can be any functional group known in the art for conjugation. Examples Petition 870260086668, dated 08 / 25 / 2026, p. 24 / 110 14 / 71 of such functional groups include, without limitation, amine, aminooxy, ketone, aldehyde, maleimidyl, thiol, alcohol, azide, 1,2,4,5-tetrazinyl, trans-cyclooctenyl, bicyclononinyl, cyclooctinyl, and protected variants thereof. In some embodiments, Z is a protected amine, protected aminooxy, ketone or protected ketone, aldehyde or protected aldehyde, maleimidyl, protected thiol, protected alcohol, azide, 1,2,4,5-tetrazinyl, trans-cyclooctenyl, bicyclononinyl, or cyclooctinyl. In some embodiments, Z is azide, ketone, or protected ketone.

[045] In the descriptions herein, it is understood that each description, variation, modality, or aspect of a portion may be combined with each description, variation, modality, or aspect of other portions, in the same manner as if each and every combination of descriptions were specifically and individually listed. For example, every description, variation, modality, or aspect given herein with respect to formula (I) may be combined with every description, variation, modality, or aspect of R1, R2, R4, X, and Z, in the same manner as if each and every combination had been specifically and individually listed. It is also understood that all descriptions, variations, modalities, or aspects of any formulas such as formula (I), (II), (III), (IV), or (V), where applicable, apply equally to other formulas detailed herein, and are equally described, in the same manner as if each and every description, variation, modality, or aspect were separately and individually listed for all formulas.For example, all descriptions, variations, modalities or aspects of formula (I), where applicable, apply equally to any of the formulas detailed herein, such as formula (II), (III), (IV), and (V), and are described in the same way as if each and every description, variation, modality or aspect were separately and individually listed for all formulas. Drug-ligand Petition 870260086668, dated 08 / 25 / 2026, p. 25 / 110 15 / 71

[046] In another aspect, a compound of formula (II) is provided, R1I R4HCR Z---(CHJn----c---C---O---C---YD R4H(II), where n, R1, R2, R4, X, and Z are as described herein for formula (I); D is a drug; Y is absent when D is a drug connected via an amine, or Y is -N(R6)CH2- when D is a drug connected via a phenol, alcohol, thiol, thiophenol, imidazole, or non-basic amine; wherein R6 is optionally substituted C1-C1 alkyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, the compound of formula (II) is a drug-linker prepared by combining the ligand of formula (I) with a drug such as a small molecule, peptide, or therapeutic protein.

[047] In some embodiments of the compound of formula (II), Y is absent. In some embodiments, Y is -N(R6)CH2-.

[048] In some embodiments of formula (II) compounds, suitable drugs include, without limitation, small molecules, peptides, proteins, and nucleic acids. Examples of suitable drugs include, without limitation, antidiabetic drugs, growth promoters, antibacterials including aminoglycosides, penicillins, cephalosporins, macrolides and peptides, trimethoprim, pyromidic acid, and sulfamethazine; analgesic and anti-inflammatory drugs, antiallergic and antiasthmatic drugs, antihypercholesterolemic drugs, beta-adrenergic blockers and antihypertensive drugs, antineoplastic drugs and antiviral drugs.

[049] Further examples of such drugs include alcohols such as paclitaxel and analogues, epothilones and analogues, camptothecin and analogues such as irinotecan, and nucleosides. Petition 870260086668, dated 08 / 25 / 2026, page 26 / 110 16 / 71 such as 5-fluorouracil and capecitabine. In another embodiment, the drug is a peptide comprising a serine residue. In another embodiment, the drug is a small molecule comprising an arylol group; examples of such drugs include SN-38, etilefrine, prenalterol, and estradiol. In another embodiment, the drug is a peptide comprising a tyrosine residue. If coupling is via S, the drug may be a small molecule comprising a thiol group. Examples of such drugs include penicillamine, captopril, and enalapril. The drug may be a small molecule comprising a thioaryl or thioheteroaryl group; examples of such drugs include 6-mercaptopurine. If coupling occurs through a non-basic N, the drug may be a small molecule or peptide comprising a primary or secondary amide (such as a pyroglutamate residue or another amide) or sulfonamide, or a heteroaryl group such as an indole (e.g., tryptophan) or purine.Examples include thyrotropin-releasing hormone, bombesin, luteinizing hormone-releasing hormone, follicle-stimulating hormone, octreotide, 5-fluorouracil, and allopurinol.

[050] Examples of nucleic acid-based drugs include the sense and antisense strands of any gene from an animal, and particularly from a mammal. Such genes may be those that are already the subject matter of antisense DNAs or RNAs, or small interfering RNAs that have been supplied for the purpose of treating various diseases, for example genes for protein kinase C-alpha, BCL-2, ICAM-1, tumor necrosis factor alpha and the like. Also included are CpG oligonucleotide agonists of toll-like receptors. Nucleic acids may be coupled directly to ligands or through a modified group in the nucleic acid, for example, an oligonucleotide comprising a 5' or 3' amine modification or comprising an amine-containing base.

[051] In some embodiments of a compound of formula (II), Petition 870260086668, dated 08 / 25 / 2026, p. 27 / 110 17 / 71 D is a peptide. Examples of suitable peptides include, without limitation, octreotide (SEQ ID NO:5), exenatide and variants including [N28Q]exenatide (SEQ ID NO:1), insulin lispro (A chain: SEQ ID NO:2; B chain: SEQ ID NO:3; disulfide bridges: A6All, A7-B7, A20-B19), or teduglutide ([Gly2]GLP-2) (SEQ ID NO:4), and sequence variants thereof. For example, for any of the sequences described herein, both the amidated and non-amidated forms are contemplated. As another example, for any of the amino acids, both the L and D forms are contemplated. In some embodiments, octreotide is D-Phe-CysPhe-D-Trp-Lys-Thr-Cys-Thr-ol (cyclic disulfide Cys2-Cys7). SEQ ID NO:1 HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSSGAPPPS-NH2([N28Q]exenatide) SEQ ID NO: 2 GIVEQCCTSICSLYQLENYCN (insulin A chain lispro) SEQ ID NO: 3 FVNQHLCGSHLVEALYLVCGERGFFYTKPT (insulin B chain lispro) SEQ ID NO: 4 HGDGSFSDEMNTILDNLAARDFINWLIQTKITD (Teduglutide ([Gly2] GLP-2) ) SEQ ID NO:5 FCFWKTCT (octreotide; cyclic disulfide Cys2Cys7) Conjugated

[052] In another aspect, a conjugate of formula is provided III) , M— r R1 Ί 1 R4 HC---R2 O 1 1 II -Z'---(CH?)n----c---C---O---C---Y---D R4 H q (III) r where n, R1, R2, R4, D, and Y are as described herein for formula (I) or (II); M is a macromolecular carrier; q is an integer from 1 to 10 when M is a soluble macromolecule, or q is a multiplicity when M is an insoluble matrix; Z* indicates coupling to M. In some embodiments, the compound of Petition 870260086668, dated 08 / 25 / 2026, p. 28 / 110 18 / 71 formula (III) is a drug conjugate D releasably linked to the macromolecular carrier M via a ligand of formula (I). It is understood that, when M is an insoluble matrix, a multiplicity of drug-ligands can be attached to M. For example, in some embodiments, when M is a hydrogel of formula (IV) in which both P1 and P2 are 4-armed polymers, 1, 2, 3, or 4 drug-ligands can be attached to each P1-P2 unit. Thus, the desired multiplicity can be achieved by reacting the drug-ligand with M at an appropriate ratio. As such, the appropriate drug concentration in the matrix volume can be achieved.

[053] In some embodiments of a conjugate of formula (III), molecular carrier M is a soluble macromolecule and q is an integer from 1 to 10. In some embodiments, M is an insoluble matrix and q is a multiplicity. In some embodiments, when M is an insoluble matrix, q is a multiplicity so that the appropriate drug concentration in the matrix volume can be achieved. Examples of soluble macromolecules include, without limitation, polyethylene glycol or other synthetic polymer, dextran, antibody, antibody fragment, albumin or other protein, of sufficient molecular size to inhibit efficient renal filtration as understood in the art. For polyethylene glycols, M may be single-chain, multi-chain, or multi-arm with an average molecular weight between 1,000 and 100,000 daltons, preferably between 1,000 and 40,000 daltons.Examples of insoluble matrices include, without limitation, hydrogel, implant, or surgical device, either in bulk or as microparticles or nanoparticles. In some embodiments, M is a soluble macromolecule. In some embodiments, M is an insoluble matrix. In some embodiments, M is a hydrogel of formula (IV) as described herein.

[054] In some embodiments of a conjugate of formula (III), the molecular carrier M comprises at least one functional group. Petition 870260086668, dated 08 / 25 / 2026, p. 29 / 110 19 / 71 Z' is cognate to Z, allowing conjugation. For example, when Z is an amine, Z' is a carboxylic acid, active ester, or active carbonate to produce a conjugate of formula (III) where Z* is an amide or carbamate. As another example, when Z is an azide, Z' is an alkynyl, bicyclononinyl, or cyclooctinyl to produce a conjugate of formula (III) where Z* is a 1,2,3-triazole. As another example, when Z is NH2O, Z' is a ketone or aldehyde to produce a conjugate of formula (III) where Z* is an oxime. As another example, when Z is SH, Z' is a maleimide or halocarbonyl to produce a conjugate of formula (III) where Z* is a thioether or thioether. Similarly, these roles of Z and Z' can be reversed to produce Z* of opposite orientation. In some embodiments, Z* comprises an amide, oxime, 1,2,3-triazole, thioether, thiosuccinimide, or ether. Hydrogel

[055] In another aspect, a hydrogel of formula (IV) is provided, L Jr(IV), where n, R1, R2, R4, and Z* are as described here for formula (I), (II), or (III); (CH2)yB (CH2)x----C----(CH2)zC* W is absent or is H, wherein each of x, y, and z is independently an integer from 0 to 6, B is -NH2, -ONH2, ketone, aldehyde, -SH, -OH, CO2H, carboxamide group, or a group comprising a cyclooctyne or bicyclononin, and C* is carboxamide, thioether, thiosuccinimidyl, triazole, or oxime; and P1 and P2 are independently r-arm polymers with molecular weights of 1-40 kDa, where r is an integer from 2 to 8. It is understood that (CH2)x connects to NH and C* connects to P2. In Petition 870260086668, dated 08 / 25 / 2026, p. 30 / 110 20 / 71 in some forms, the formula hydrogel (IV) is degradable.

[056] In some embodiments of a hydrogel of formula (IV), P1 and P2 are synthetic polymers such as polyethylene glycols, dextrans, hyaluronic acids, and the like. An illustrative structure of such a hydrogel is given in Figure 6. In these hydrogels, the ligands of formula (I) are used to crosslink polymer chains to form an insoluble three-dimensional matrix. These crosslinks slowly cleave by non-hydrolytic beta elimination at rates governed by the R1 and R2 groups to give finally soluble polymer fragments. These hydrogels allow the attachment of drug-ligands in various ways. When W is present, functional group B is introduced into each crosslink. As illustrated in Figure 6, the hydrogel can be formed so that a multiplicity of B is present.Group B can then either be used directly for drug-ligand attachment if B is equivalent to the cognate group Z' discussed above, or B can be derivatized to introduce the cognate group Z' for subsequent drug-ligand attachment to the preformed hydrogel. This is advantageous when the hydrogel needs to be made ex vivo, for example, by fabrication in desired shapes such as microspheres or sheets of fixed dimension. Alternatively, group B can comprise a drug-ligand of formula (II) at the time the hydrogel is prepared; this is advantageous when in situ gelation is desired by injection of a liquid mixture of components prior to gel formation. Pharmaceutical compositions

[057] In another aspect, pharmaceutical compositions comprising macromolecular carrier-drug conjugates or pharmaceutically acceptable salts thereof together with a pharmaceutically acceptable buffer and / or excipient are provided herein. Buffers are chosen so that the stability of the ligand is maintained during storage and after reconstitution if necessary, and typically have a pH between 2 and 7, preferably Petition 870260086668, dated 08 / 25 / 2026, page 31 / 110 21 / 71 between 2 and 6, and more preferably between 2 and 5. Acceptable buffers include acetic acid, citric acid, phosphoric acid, histidine, gluconic acid, aspartic acid, glutamic acid, lactic acid, tartaric acid, succinic acid, malic acid, fumaric acid, alpha-ketoglutaric acid, and the like. Excipients may include tonicity and osmolality agents such as sodium chloride; preservatives such as citric acid or a citrate salt, and parabens; antibacterials such as phenol and cresol; antioxidants such as butylated hydroxytoluene, vitamin A, C, or E, cysteine ​​and methionine; density modifiers such as sucrose, polyols, hyaluronic acid, and carboxymethylcellulose. These formulations can be prepared by conventional methods known to those skilled in the art, for example, as described in “Remington's Pharmaceutical Science,” A.R. Gennaro, ed., 17th edition, 1985, Mack Publishing Company, Easton, PA, USA.Pharmaceutical compositions may be supplied as a liquid solution or suspension, or as a solid, for example, by lyophilization of a liquid composition. Such lyophilized products may additionally comprise bulking agents to ensure rapid and efficient reconstitution before use. Methods of use

[058] In another aspect, the macromolecular drug-carrier conjugates currently described and pharmaceutical compositions comprising them can be used to treat or prevent a disease or condition in an individual. In some embodiments, methods are provided for treating a disease or condition comprising administering to the individual in need thereof a macromolecular drug-carrier conjugate described herein or pharmaceutical compositions comprising a macromolecular drug-carrier conjugate described herein. The “individual” may be a human, or it may be an animal, such as a cat, dog, cow, rat, mouse, horse, rabbit, or Petition 870260086668, dated 08 / 25 / 2026, page 32 / 110 22 / 71 another domesticated animal.

[059] Compositions containing a macromolecular carrier-drug conjugate described herein are also provided for use in the treatment of a disease or condition. Also provided herein is the use of a macromolecular carrier-drug conjugate described herein in the manufacture of a medicament for the treatment of a disease or condition.

[060] The applicable disease or condition requiring treatment will be known to those skilled in the art from the nature of the conjugated drug. For example, exenatides and insulin can be used in the treatment of diabetes, octreotide in the treatment of acromegaly and various cancers, teduglutide in the treatment of short bowel syndrome, and SN-38 and TLR9 agonists in the treatment of cancers. Any appropriate route of administration for humans and animals is provided for by the invention, for example, intravenous, intrathecal, intraocular, subcutaneous, intra-articular, intraperitoneal, or other localized injection, or by oral administration. Binder preparation

[061] The ligands of formula (I) can be prepared by any of several routes as illustrated in the following working examples. In one method, a geminal-dialkyl carbonyl compound (A) is condensed with R1R2CH2 through the action of a base. R4O I II Z----(CHj)n----C---C---R'° + R'R-'CH, I R4(A) R' R4HCR | | activation Z---(CH2)„----C---COH I base R' R4HC---R2 R' R4HC---R2O Z---(CHjln----C---C---O---CX IH reduction

[062] Appropriate bases are those capable of deprotonating Petition 870260086668, dated 08 / 25 / 2026, p. 33 / 110 23 / 71 R1R2CH2, such as potassium tert-butoxide or tert-pentoxide, lithium butyl, lithium diisopropylamide, NaH, and silazide bases such as LiHMDS, NaHMDS, or KHMDS. R10 can be H, C1-C6 alkoxy, or N(Me)OMe. When R10 is H, the alcohol (C) is produced directly. When R10 is different from H, a ketone (B) is produced, which is subsequently reduced to alcohol (C). Suitable reducing agents include borohydrides such as LiBH4 and NaBH4, although other reducing agents known in the art may be used depending on the nature of the Z group. The alcohol (C) is then activated to produce the ligand of formula (I).Typical activation conditions include conversion to chloroformate (X = Cl) through the action of phosgene or a phosgene equivalent such as diphosgene or triphosgene; conversion to succinimidyl carbonate (X = OSu) using N,N'-disuccinimidyl carbonate and 4-(dimethylamino)pyridine or by treatment of chloroformate with N-hydroxysuccinimide and pyridine; and conversion to an active carbonate, for example, by reaction with nitrophenyl chloroformate in the presence of a weak base such as pyridine. [0 63]Ligands of formula (I) wherein X is -N(R6)CH2Cl can be prepared as described in US Patent 8,754,190.

[064] Z can be any functional group known in the art for conjugation, such as amine, aminooxy, ketone, aldehyde, maleimidyl, thiol, alcohol, azide, 1,2,4,5-tetrazinyl, transcyclooctenyl, bicyclononinyl, cyclooctinyl, and protected variants thereof. In some embodiments, Z is a protected amine, protected aminooxy, ketone or protected ketone, aldehyde or protected aldehyde, maleimidyl, protected thiol, protected alcohol, azide, 1,2,4,5-tetrazinyl, transcyclooctenyl, bicyclononinyl, or cyclooctinyl. In some embodiments, Z is an azide, ketone, or protected ketone. Preparation of drug-ligands

[065] The ligand of formula (I) can be reacted with a drug D to produce the drug-ligand of formula (II), Petition 870260086668, dated 08 / 25 / 2026, p. 34 / 110 24 / 71 R1 R4HC---R2O Z---(CHJn----C---C---O---C---Y---D R4H (II) .

[066] Suitable drugs for use in the invention include small molecules, peptides, proteins, and nucleic acids. For drugs comprising basic amine groups, ligands of formula (I) wherein X is an active halide or ester are reacted with the drugs, in the presence of a base in an organic solvent or in buffered aqueous solution, to produce the drug-ligand of formula (II). Such basic amines may be part of a small molecule drug, or may be the N-terminal amines or lysine and amines of peptides and proteins. In the case of drugs with multiple basic amines, for example, peptide and proteins, more than one ligand may be attached.For synthetic peptides, the ligand can be fixed at specific locations during synthesis, for example, either at the N-terminus using the ligand in the final coupling step, or through the use of a temporary locking group or an internal amino acid residue that can be selectively removed; acylation with the ligand is then followed by overall deprotection and purification of the ligand-peptide. Suitable bases to facilitate ligand binding to the drug include tertiary amines, such as triethylamine or N,N-diisopropylethylamine, and guanidines, such as N,N-dimethylguanidine and 7-methyl-1,5,7-triazabicyclo[4.4,0]dec-5-ene, and others known in the art. When carried out in aqueous solution, the reaction is typically performed with pH values ​​between 7 and 10.

[067] The ligands of formula (I) wherein X = N(R6)CH2C1 can be used to bind to drugs via alcohols, phenols, thiols, thiophenols, imidazoles, and non-basic nitrogen atoms, similarly to methods described in U.S. Patent 8,754,190. Petition 870260086668, dated 08 / 25 / 2026, p. 35 / 110 25 / 71

[068] Once the drug-ligands are prepared, any protecting groups for Z or the drug can be removed before conjugation using procedures well known in the art. Preparation of conjugates

[069] 0 The drug-ligand of formula (II) can be used to prepare the conjugate of formula (III) by reacting the unprotected functional group Z with a cognate reactive group attached to the macromolecular carrier M, Γ R1π IR* HC---R2O M—|-Z· (CH2)n----CCOCYD

[070] Z can be any functional group known in the art for conjugation, including amine, aminooxy, ketone, aldehyde, maleimidyl, thiol, alcohol, azide, 1,2,4,5-tetrazinyl, transcyclooctenyl, bicyclononinyl, or cyclooctinyl. The choice of connecting functionality will depend on the presence of other functional groups in drug D, but will be clear to those skilled in the art. M can be a water-soluble polymer, for example, a polyethylene glycol or other synthetic polymer, dextran, antibody, antibody fragment, albumin, or other protein, of sufficient molecular size to inhibit efficient renal filtration as understood in the art. For polyethylene glycols, M can be single-chain, multi-chain, or multi-arm with an average molecular weight between 1,000 and 100,000 daltons, preferably between 1,000 and 40,000 daltons. Polyethylene glycol comprises at least one Z' functional group cognate to Z that allows conjugation.For example, when Z is an amine, Z' is a carboxylic acid, active ester, or active carbonate to produce a conjugate of formula (III) in which Z* is an amide or carbamate. As another example, when Z is an azide, Z' is an alkynyl. Petition 870260086668, dated 08 / 25 / 2026, page 36 / 110 26 / 71 bicyclononyl, or cyclooctinyl to produce a conjugate of formula (III) where Z* is 1,2,3-triazole. As another example, when Z is NH2O, Z' is a ketone or aldehyde to produce a conjugate of formula (III) where Z* is an oxime. As another example, when Z is SH, Z' is a maleimide or halocarbonyl to produce a conjugate of formula (III) where Z* is a thio-succinimidyl or thioether. Similarly, these roles of Z and Z' can be reversed to produce Z* of opposite orientation. These conjugation reactions can be carried out under conditions known in the art, for example, when Z = azide and Z' = cyclooctyne, conjugation occurs in any solvent in which both components show adequate solubility, although it is known that aqueous solutions show more favorable reaction rates.

[071] Similarly, M can be a water-insoluble matrix, for example, a hydrogel, implant, or surgical device, either crude or as microparticles or nanoparticles. In this case, M comprises a multiplicity of Z groups as described above, allowing the attachment of a multiplicity of drug-ligands. Although the matrix is ​​insoluble, the reaction with a solution comprising the drug-ligand is sufficient for conjugation to occur. For example, when the insoluble matrix is ​​a hydrogel, either crude or manufactured as microspheres or other particulate forms, a solution of the drug-ligand is mixed with a hydrogel suspension for a sufficient time to allow the drug-ligand to penetrate the porous hydrogel matrix and conjugation to occur. Preparation of hydrogels

[072] In some embodiments, M is a biodegradable hydrogel of formula (IV), wherein P1, P2, Z*, n, r, R1, R2, R4, and W are as described Petition 870260086668, dated 08 / 25 / 2026, p. 37 / 110 27 / 71

[073] An illustrative structure of such a hydrogel comprising crosslinks of formula (IV) is given in Figure 6. In these hydrogels, ligands of formula (I) are used to crosslink polymer chains to form an insoluble three-dimensional matrix. The crosslinks cleave slowly by non-hydrolytic beta elimination at rates governed by the R1 and R2 groups to give finally soluble polymer fragments. These hydrogels allow the attachment of drug-ligands in several ways. When W is present, functional group B is introduced into each crosslink. As illustrated in Figure 6, the hydrogel can be formed first to provide a hydrogel polymer in which a multiplicity of B is present to provide a degradable polymer that does not additionally comprise a drug-ligand of formula (II).Group B can then either be used directly for drug-ligand attachment if B is equivalent to the cognate group Z' discussed above, or B can be derivatized to introduce the cognate group Z' for subsequent drug-ligand attachment to the pre-formed hydrogel. This is advantageous when the hydrogel needs to be made ex vivo, for example, by fabrication into desired shapes such as microspheres or sheets of fixed dimension. Alternatively, group B can comprise a drug-ligand of formula (II) at the time the hydrogel is prepared; this is advantageous when in situ gelation is desired by injection of a liquid mixture of components prior to gel formation.

[074] These hydrogels can be formed by mixing two multi-armed prepolymers, one having arms terminating in a group comprising the residue of a binder of formula (I) with Petition 870260086668, dated 08 / 25 / 2026, page 38 / 110 28 / 71 the reactive end group Z, and another having arms terminating in a group comprising cognate reactive end group Z'. In one embodiment, a prepolymer has the formula (V) R1 R4HC—R2O II II HZ—(CH2)nc—c—o—c—N—W--P2 R4H Jr(v) wherein the groups are as defined above, and the other prepolymer has the formula P1-(Z,)r. When mixed in a suitable solvent, typically an aqueous buffer at a pH of 2-7 when Z and Z' are azide / cyclooctine, or at a pH of 6-9 when Z and Z' are an activated ether and an amine, the Z and Z' groups react to form an insoluble hydrogel matrix comprising crosslinks of formula (IV). This process can be carried out in the crude phase, or under emulsification conditions in a mixed organic / aqueous system in order to form microparticle suspensions such as microspheres that are suitable for injection.

[075] Certain representative modalities are provided below:

[076] Modality 1. A ligand of formula (I) R1 R4HC---R2O I III z---(CHJn----c---c---O---CX R4H(I) where n = 1-6, or both R1 and R2 are independently electron-withdrawing groups, or one of R1 and R2 is an electron-withdrawing group and the other is alkyl, or H; Each R4 is independently a C1-C3 alkyl group, or taken together they can form a 3-6 membered ring; Z is a group for attaching the binder to a carrier. Petition 870260086668, dated 08 / 25 / 2026, p. 39 / 110 29 / 71 conjugation; and X is an exit group. [ 077 ] Embodiment 2. 0 ligand of embodiment 1 wherein X is halogen, N-succinimidyloxy, nitrophenoxy, penta-halophenoxy, imidazolyl, triazolyl, or tetrazolyl. [ 078 ] Embodiment 3. The ligand of embodiment 1 wherein Z is a protected amine, protected aminooxy, ketone or protected ketone, aldehyde or protected aldehyde, maleimidyl, protected thiol, protected alcohol, azide, 1,2,4,5-tetrazinyl, trans-cyclooctenyl, bicyclononyl, or cyclooctinyl.

[079] Modality 4. A drug-ligand of formula (II) R1 I R4HC---R2O I III z---(CHJn----C---C---O---CY D R4H(II) wherein Y is absent when D is a drug connected via an amine, or Y is N(R6)CH2 when D is a drug connected via a phenol, alcohol, thiol, thiophenol, imidazole, or nonbasic amine wherein R6 is optionally substituted C1-C1e alkyl or aryl or optionally substituted heteroaryl.

[080] Modality 5. A conjugate of ΓRl I R4HC---R2formula (III) where M is a macromolecular carrier, Z* comprises a carboxylic amide, oxime, 1,2,3-triazole, thioether, thiosuccinimide, or ether, eq = 1-multiplicity.

[081] Modality 6. A hydrogel of formula (IV), Petition 870260086668, dated 08 / 25 / 2026, p. 40 / 110 30 / 71 R' R4HC---R2p'--Z--(CH2)n---c — c—o —11 H, C---N--W--P2(IV) where P1 and P2 are independently r-arm polymers where r = 2-8, and W is absent or is (CHzjyB ((CH^---C---(CH2)2C· H where x, y, and z are each independently 0-6; B is nh2 ONH2, ketone, aldehyde, SH, OH, CO2H, or carboxamide group w C* is carboxamide, thioether, thio-succinimidyl, triazole, or oxime.

[082] The following examples are offered to illustrate, but not to limit, the description. Example 1 Preparation of ligands of formula (I) where Z = azide O H Me 2. NaN3 1. TfjjO. lubdine r'r2ch2 N3 OMe KO'Bu O ν3 R' R2 NaBH4 OH R1ν3 R2 ν3 O R' R2(1) 4-azido-1-cyano-3,3-dimethyl-2butyl succinimidyl carbonate (Formula (I) where n = 1, R1= GN, R2= H, R4= CHa, Z AL, and X = succinimidyloxy) .

[083] A 1 M solution of potassium tert-butoxide in THE (3.5 mL, 3.5 mmol) was added to a solution of methyl 3-azido-2,2-dimethylpropionate (prepared according to Kim Synthetic Communications; 300 mg, 1.9 mmol) and acetonitrile (0.3 mL, 7.0 mmol) in 7 mL of THE -30°C. The mixture was Petition 870260086668, dated 08 / 25 / 2026, p. 41 / 110 31 / 71 was stirred for 30 min at -30°C, then allowed to warm to room temperature for 1 hour and stirred for an additional 30 min. The mixture was cooled over ice and quenched by the addition of 6 N HCl (0.62 mL, 3.7 mmol), then divided between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organics were washed with brine, dried over MgSO4, filtered, and concentrated to give the crude ketone.

[084] Sodium borohydride (33 mg, 0.88 mmol) was added to a solution of the crude ketone (300 mg, about 1.75 mmol) in 7 mL of methanol. The mixture was stirred for 15 min, then quenched by the addition of 6 N HCl (0.7 mL), and divided between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organics were washed with brine, dried over MgSO4, filtered, and concentrated to give the crude alcohol. Purification in SiO2 (20-40% EtOAc / hexane) yielded 4-azido-1-cyano-3,3-dimethyl-2-butanol (142 mg, 0.85 mmol). 1H-NMR (CDC1a, 300 MHz) d 3.83-3.92 (m,1H), 3.43 (d, J=12.1 Hz,1H), 3.21 (d, J=12.1 Hz, 1H), 2.41-2.62 (m,3H), 0.97 (s,3H), and 0.96 (s,3H).

[085] Pyridine (136 μΣ, 1.7 mmol) was added dropwise to a solution of 4-azido-1-cyano-3,3-dimethyl-2-butanol (142 mg, 0.85 mmol) and triphosgene (425 mg, 1.44 mmol) in 8 mL of ice-cooled THF. The resulting suspension was allowed to warm to room temperature and stirred for 15 min, then filtered and concentrated to provide crude chloroformate. This was dissolved in 8 mL of ice-cooled THF and treated with N-hydroxysuccinimide (291 mg, 2.5 mmol) and pyridine (204 μΣ, 2.53 mmol). The resulting suspension was allowed to warm to room temperature and stirred for 15 min, then divided between EtOAc and 5% KHSO4. The aqueous phase was extracted twice with EtOAc, and the combined organics were washed with brine, dried over MgSO4, filtered, and concentrated to give crude succinimidyl carbonate. Purification in SiO2 (20-40% EtOAc / hexane) yielded 4-azido-1-cyano-3,3-dimethyl succinimidyl carbonate. Petition 870260086668, dated 08 / 25 / 2026, page 42 / 110 32 / 71 2-butyl (174 mg, 0.56 mmol).1H-NMR (CDCI3, 300 MHz) d 5.03 (dd,J=7.0, 5.1.1H), 3.27-3.41 (m,6H), 3.43 (d, J=12.1 Hz,1Hz), 3.43 (d, J=12.1 Hz,1Hz), 1H), 2.41–2.62 (m.3H), 0.97 (s.3H), and 0.96 (s.3H). (2)Succinimidyl carbonate of 4-azido-1- ( (N,Ndimethylamino)sulfonyl)-3,3-dimethyl-2-butyl (Formula (I) in which n = 1, R1= SO2N(CH3)2, R2= H, R4= CH , Z = N3, and Xximidil = succinimide).

[086] A 1.43 M solution of n-butyllithium in hexane (70 mL, 100 mmol) was added to a stirred solution of N,N-dimethylmethanesulfonamide (12.33 g, 100 mmol) in 200 mL of anhydrous THF maintained at -50°C under an inert atmosphere. The mixture was allowed to warm to -20°C for 1 h, then cooled again to -50°C before adding methyl 3-azido-2,2-dimethylpropionate (prepared according to Kim, Synthetic Communications; 7.70 g, 50 mmol). The mixture was allowed to warm to +10°C for 2 h, then quenched with 20 mL of 6 N HCl. The mixture was diluted with methyl tert-butyl ether (MTBE, 200 mL), washed with 2 x 100 mL of water and 1 x 100 mL of brine, dried over MgSO4, filtered, and concentrated to yield 14.05 g of crude ketone product. Chromatography on SiO2 (220 g) using a gradient step of 0, 20, 30, 40, and 50% EtOAc / hexane yielded purified 4-azido-1-((N,N-dimethylamino)sulfonyl)-3,3-dimethyl-2-butanone (10.65 g, 86%) as a crystalline solid.

[087] The above ketone was dissolved in 200 mL of methanol, cooled over ice, and treated with sodium borohydride (0.96 g, 25 mmol) for 15 min before quenching with 4 mL of 6 N HCl and concentrated. The resulting fluid paste was diluted with methyl tert-butyl ether (MTBE, 200 mL), washed with 1 x 100 mL of water and 1 x 100 mL of brine, dried over MgSO4, filtered, and concentrated to yield 10.0 g of crystalline 4-azido-1-((N,N-dimethylamino)sulfonyl)-3,3-dimethyl-2-butanol.

[088] Pyridine (10.6 mL, 132 mmol) was added over 10 Petition 870260086668, dated 08 / 25 / 2026, page 43 / 110 33 / 71 min in a stirred mixture of N-hydroxysuccinimide (6.90 g, 60 mmol) and triphosgene (5.93 g, 20 mmol) in 250 mL of ice-cooled dichloromethane. The mixture was stirred for 15 min on ice, then allowed to warm to room temperature for 30 min. A solution of 4-azido-1-((N,N-dimethylamino)sulfonyl)-3,3-dimethyl-2-butanol (10.0 g, 40 mmol) in 20 mL of dichloromethane was added and the mixture was stirred for an additional 1 h at room temperature. After cooling on ice, the mixture was treated with 100 mL of and the phases were separated. The organic phase was washed twice with water, once with 5% KHSO4, and once with brine, dried over MgSO4, filtered, and concentrated. The crude product was crystallized from 100 mL of 30% EtOAc / hexane, giving 4-azido-1-((N,N-dimethylamino)sulfonyl)-3,3-dimethyl-2-butyl succinimidyl carbonate (11.1 g, 71%) as a white crystalline solid. (3) Additional compounds of formula (I) prepared according to these procedures include:

[089] Succinimidyl carbonate of 4-azido-1-(methylsulfonyl)3,3-dimethyl-2-butyl (Formula I in which n = 1, R1 = SO2CH3, R2 = H, R4 = CH3, Z = N3, and X = succinimidyloxy).

[090] Succinimidyl carbonate of 4-azido-1-((4-methyl piperidinyl)sulfonyl)-3,3-dimethyl-2-butyl (Formula I em in which n = 1, R1 = SO2N(CH2CH2)2CHCHs, R2= H, R4= CH3, Z = Xxi, and N3, and Xximidi = succinyl). LC / MS showed [M+H]+ = 446.15.

[091] Succinimidyl carbonate of 4-azido-1-(phenylsulfonyl)3,3-dimethyl-2-butyl (Formula I in which n = 1, R1 = SO2Ph, R2= H, R4= CH3, Z = N3, and X = succinimidyloxy).

[092] Succinimidyl carbonate of 4-azido-1-(4chlorophenylsulfonyl)-3,3-dimethyl-2-butyl (Formula I in which n = 1, R* 1= SO2PhCl, R2= H, R4= CH3, Z = N3, and X = succinimidyloxy) .

[093] Succinimidyl carbonate of 4-azido-1-(4morpholinossulfonyl)-3,3-dimethyl-2-butyl (Formula I in which n = 1, R1= SO2N(CH2CH2)2O, R2= H, R4= CH3, Z = N3, and Xxi = succinimidyl). Petition 870260086668, dated 08 / 25 / 2026, p. 44 / 110 34 / 71

[094] 4-azido-1(isopropylsulfonyl)-3,3-dimethyl-2-butyl succinimidyl carbonate (Formula I where n = 1, Ri = SO2CH(CH3)2, R2= H, R4= CH3, Z = N3, and X = succinimidyloxy).

[095] 4-azido-1-((N-ethyl-Nmethylamino)sulfonyl)-3,3-dimethyl-2-butyl succinimidyl carbonate (Formula I where n = 1, R1 = SO2N (CH3) (CH2CH3) , R2 = H, R4 = CH3, Z = N3, and X = succinimidyloxy).

[096] 4-azido-l-((N,N-bis(2methoxyethyl) aminosulfonyl)-3,3-dimethyl-2-butyl succinimidyl carbonate (Formula I where n = 1, R1 = SO2N (CH2CH2OCH3) 2, R2 = H, R4 = CH3, Z = N3, and X = succinimidyloxy).

[097] 4-azido-1-(4methylphenylsulfonyl)-3,3-dimethyl-2-butyl succinimidyl carbonate (Formula I where n = 1, R1 = SO2PhCH3, R2 = H, R4 = CH3, Z = N3, and X = succinimidyloxy). Example 2 Preparation of binders of formula (I) CI(CH2}nBr KO'Bu R1R2CH2base acetone / h2o (Cl2CO) HOSu, pyr NaBH4 MeOH

[098] Another general method for the preparation of compounds of formula (I) is illustrated for the cases where n = 2 or 3, R1 = ON, R2 = H, both R4 = CH3, Z = N3, and X = N-succinimidyloxy. 5-Azido-1-cyano-3,3-dimethyl-2-pentyl succinimidyl carbonate Petition 870260086668, dated 08 / 25 / 2026, p. 45 / 110 35 / 71 (Formula I where n = 2, R1 = CN, R2 = H, R4 = CH, Z = N3, and X = succinimidyloxy). (a) Ethyl 4-chloro-2,2-dimethylbutanoate.

[099] A 500 mL round-bottom flask, dried with a heat gun and fitted with a stirring rod, rubber septum, nitrogen inlet, and thermocouple probe, was loaded with iPr2NH (5.30 mL, 37.4 mmol, 1.1 equiv, 0.27 M final concentration) and THF (100 mL). The reaction mixture was cooled to 0°C while a solution of nBuLi (1.28 M in hexanes, 27.8 mL, 35.7 mmol, 1.05 equiv, 0.26 M final concentration) was added dropwise via syringe at a rate such that the internal temperature did not exceed +10°C (~10 min). The reaction mixture was stirred at 0°C for 15 min, cooled to -78°C, and a solution of ethyl isobutyrate (4.6 mL, 4.0 g, 34 mmol, 1.0 equiv, 0.24 M final concentration) in THF (5 mL) was added dropwise through a syringe at a rate such that the internal temperature did not exceed -65°C (~5 min).The reaction mixture was stirred at -78°C for 45 min, then a solution of 1-bromo-2-chloroethane (2.8 mL, 34 mmol, 1.0 equiv, 0.24 M final concentration) in THF (5 mL) was added at a rate such that the internal temperature did not exceed -68°C. The reaction mixture was stirred at -78°C for 15 min, allowed to warm to 0°C, and stirred at 0°C for 15 min. The reaction mixture was diluted with EtOAc (100 mL) and 5% KHSO4 (100 mL). The aqueous phase was separated and extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with brine, dried over MgSO4, filtered, and concentrated from toluene (10 mL x 2) to provide 4.85 g (27 mmol, 79%) of the desired chloride as a pale yellow oil. 1H NMR (CDCl3, 300 MHz) δ 4.14 (q, J=7.2 Hz, 2 H), 3.43 3.57 (m, 2 H), 1.94 - 2.19 (m, 2 H), 1.27 (t, J=7.1 Hz, 3 H), 1.22 (s, 6 H). (b) Ethyl 4-azido-2,2-dimethylbutanoate. Petition 870260086668, dated 08 / 25 / 2026, page 46 / 110 36 / 71

[100] A 100 mL round-bottom flask, fitted with a stirring bar, rubber septum, and nitrogen inlet, was charged with ethyl 4-chloro-2,2-dimethylbutanoate (2-1) (4.85 g, 27 mmol, 1.0 equiv, 0.54 M final concentration), DMSO (50 mL), and sodium azide (2.28 g, 35 mmol, 1.3 equiv, 0.70 M). The reaction mixture was stirred behind an explosion-proof shield at 70°C for 18 h. The reaction mixture was cooled to room temperature and diluted with EtOAc (200 mL) and H2O (100 mL). The organic phase was separated, washed with H2O (3 x 100 mL) and brine (100 mL), dried over MgSO4, filtered, and concentrated. Purification by column chromatography (40 g silica gel cartridge; stepwise gradient elution: 0%, 5%, 10%, 20% EtOAc / hexanes) yielded 4.33 g (23.3 mmol, 87%) of the desired azide as a pale yellow oil. 1H NMR (CDCl3, 300 MHz) δ 4.15 (q, J=7.1 Hz, 2 H), 3.22 3.35 (m, 2 H), 1.81 - 1.96 (m, 2 H), 1.27 (t, J=7.2 Hz, 3 H), 1.15 - 1.24 (m, 6 H). (c) 5-azido-1-cyano-3,3-dimethyl-2-pentanone.

[101] A 100 mL round-bottom flask dried with a heat gun, fitted with a stirring rod, rubber septum, nitrogen inlet, and thermocouple probe was charged with THF (20 mL) and iPr2NH (1.59 mL, 11.3 mmol, 2.1 equiv, 0.36 M final concentration). The solution was cooled to 0°C while a solution of nBuLi (1.28 M in hexanes, 8.64 mL, 10.8 mmol, 2.0 equiv, 0.34 M final concentration) was added dropwise at a rate such that the internal temperature did not exceed +10°C (~5 min), stirred at 0°C for 10 min, and cooled to -78°C. Acetonitrile (0.59 mL, 11.3 mmol, 2.1 equiv, 0.36 M final concentration) was added dropwise via syringe at a rate such that the internal temperature did not exceed -65°C. The mixture of Petition 870260086668, dated 08 / 25 / 2026, p. 47 / 110 The reaction mixture was stirred at -78°C for 15 min, and then a solution of ethyl 4-azido-2,2-dimethylbutanoate (1.0 g, 5.4 mmol, 1.0 equiv, 0.17 M final concentration) in THF (5 mL) was added via syringe so that the internal temperature did not exceed -65°C (~3 min). The reaction mixture was stirred at -78°C for 10 min, allowed to warm to 0°C, and stirred at 0°C for 15 min. The reaction mixture was diluted with EtOAc (50 mL) and 5% KHSO4 (50 mL). The aqueous layer was separated and extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with brine (50 mL), dried over MgSO4, filtered, and concentrated. Purification by column chromatography (40 g silica gel cartridge; step-by-step gradient elution: 20%, 30%, 50%) EtOAc / hexanes) yielded 537 mg (2.98 mmol, 55%) of the desired ketone as a pale yellow oil: 1H NMR (CDCl3, 300 MHz) δ 3.66 (s, 2 H), 3.37 (t, J=6.7 Hz, 2 H), 1.86 (t, J=6.8 Hz, 2 H), 1.16 - 1.27 (m, 6 H); d)) 5-azido-1 -cyano-3,3-dimethyl-2-pentanol.

[102] A 25 mL round-bottom flask, fitted with a stirring bar, rubber septum, and nitrogen inlet, was charged with 5-azido-1-cyano-3,3-dimethyl-2-pentanone (537 mg, 2.98 mmol, 1.0 equiv, 0.25 M final concentration) and MeOH (12 mL) and cooled to 0°C. NaBH4 (56 mg, 1.49 mmol, 0.5 equiv, 0.13 M final concentration) was added as a solid in a single portion. The reaction mixture was stirred at 0°C for 30 min. The reaction mixture was diluted with EtOAc (50 mL) and 5% aq KHSO4 (50 mL). The aqueous phase was separated and extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with brine (40 mL), dried over MgSO4, filtered, and concentrated. Purification by column chromatography (40 g silica gel cartridge; stepwise gradient elution: 20%, 30%, 40%, 50% EtOAc / hexanes) yielded 482 mg (2.64 mmol, 89%) of alcohol. Petition 870260086668, dated 08 / 25 / 2026, page 48 / 110 38 / 71 desired as a pale yellow oil: 1H NMR (CDCl3, 300 MHz) δ 3.76 (ddd, J=9.1, 5.4, 3.4 Hz, 1 H), 3.34 - 3.50 (m, 2 H), 2.38 - 2.64 (m, 3 H), 1.68 - 1.82 (m, 1 H), (ddd, J=14.1, 7.4, 6.6 Hz, 1H), 0.96(s,3H), 0.94(s,3H). (e) Succinimidyl carbonate of 5-azido-1-cyano-3,3-dimethyl2-pentyl.

[103] A 50 mL round-bottom flask, dried with a heat gun and fitted with a stirring rod, rubber septum, and nitrogen inlet, was loaded with NHS (455 mg, 3.96 mmol, 1.5 equiv, 211 mM final concentration), DCM (17 mL), and triphosgene (392 mg, 1.32 mmol, 0.5 equiv, 70.4 mM final concentration) and cooled to 0°C. The reaction mixture was cooled to 0°C while pyridine (0.774 mL, 8.71 mmol, 3.3 equiv, 464 mM final concentration) was added dropwise via a syringe. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 30 min. A solution of 5-azido-1-cyano-3,3-dimethyl-2-pentanol (482 mg, 2.64 mmol, 1.0 equiv, 150 mM final concentration) in THF (1 mL) was added dropwise using a syringe. The reaction mixture was stirred at room temperature for 1 h, cooled to 0°C, and quenched by the addition of H2O (10 mL). The reaction mixture was further diluted with EtOAc (50 mL) and H2O (50 mL).The organic phase was separated and washed with water (50 mL), 5% aq. KHSO4, brine (50 mL), dried over MgSO4, filtered and concentrated. Purification by column chromatography (40 g silica gel cartridge; stepwise gradient elution: 25%, 30%, 35%, 40% acetone / hexanes) yielded 636 mg (1.96 mmol, 75% yield) of desired activated ligand as a white solid. 1H NMR (CDCl3, 300 MHz) δ 4.90 - 4.99 (m, 1 H), 3.32 - 3.50 Petition 870260086668, dated 08 / 25 / 2026, page 49 / 110 39 / 71 (m, 2 H), 2.84 - 2.88 (m, 4 H), 2.66 - 2.82 (m, 2 H), 1.58 1.80 (m, 2 H), 1.08 (s, 6 H). (2) 6-azido-1-cyano-3,3-dimethyl2-hexyl succinimidyl carbonate (Formula I where n = 3, R1 = CN, R2 = H, R4 = CH3, Z = N3, and X = succinimidyloxy). (a) Ethyl 5-chloro-2,2-dimethylpentanoate. 0

[104] A 500 mL round-bottom flask, dried with a heat gun and equipped with a stirring rod, rubber septum, nitrogen inlet, and thermocouple probe, was loaded with iPr2NH (5.30 mL, 37.4 mmol, 1.1 equiv, 266 mM final concentration) and THF (100 mL). The reaction mixture was cooled to 0°C while a solution of nBuLi (1.28 M in hexanes, 27.8 mL, 35.7 mmol, 1.05 equiv, 254 mM final concentration) was added dropwise via syringe at a rate such that the internal temperature did not exceed +10°C (~10 min). The reaction mixture was stirred at 0°C for 15 min, cooled to -78°C, and a solution of ethyl isobutyrate (4.60 mL, 4.0 g, 34.0 mmol, 1.0 equiv, 242 mM final concentration) in THF (5 mL) was added dropwise through a syringe at a rate such that the internal temperature did not exceed -65°C (~5 min).The reaction mixture was stirred at -78°C for 45 min, then a solution of 1-bromo-3-chloropropane (3.37 mL, 34.0 mmol, 1.0 equiv, 242 mM final concentration) in THF (5 mL) was added at a rate such that the internal temperature did not exceed -68°C. The reaction mixture was stirred at -78°C for 15 min, allowed to warm to 0°C, and stirred at 0°C for 15 min. The reaction mixture was diluted with EtOAc (100 mL) and 5% KHSO4 (100 mL). The aqueous phase was separated and extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with brine, dried over MgSO4, filtered, and concentrated with toluene (10 mL x 2). 6.17 g (32.0 mmol, 90%) of the desired chloride were obtained as a pale yellow oil. 1H NMR (CDCl3, 300 MHz) δ 4.13 (q, J=7.2 Hz, 2 H), 3.49 Petition 870260086668, dated 08 / 25 / 2026, p. 50 / 110 40 / 71 3.56 (m, 2 H), 1.62 - 1.83 (m, 4 H), 1.26 (t, J=7.1 Hz, 3 H), 1.17 - 1.22 (m, 6 H). (b) Ethyl 5-azido-2,2-dimethylpentanoate.

[105] A 100 mL round-bottom flask, fitted with a stirring bar, rubber septum, and nitrogen inlet, was charged with ethyl 5-chloro-2,2-dimethylpentanoate (6.17 g, 32.0 mmol, 1.0 equiv, 533 mM final concentration), DMSO (60 mL), and sodium azide (2.7 g, 42 mmol, 1.3 equiv, 690 mM). The reaction mixture was stirred behind an explosion shield at 70°C for 18 h. The reaction mixture was cooled to room temperature and diluted with EtOAc (200 mL) and H2O (100 mL). The organic phase was separated, washed with H2O (3 x 100 mL) and brine (100 mL), dried over MgSO4, filtered, and concentrated. Purification by column chromatography (40 g silica gel cartridge; stepwise gradient elution: 0%, 5%, 10%, 20% EtOAc / hexanes) yielded 5.40 g (27.1 mmol, 85%) of the desired azide as a pale yellow oil. 1H NMR (CDCl3, 300 MHz) δ 4.13 (q, J=7.0 Hz, 2 H), 3.26 (t, J=5.9 Hz, 2 H), 1.46 - 1.65 (m, 4 H), 1.26 (t, J=7.2 Hz, 3 H), 1.19 (s, 6 H). (c) 6-azido-1-cyano-3,3-dimethyl-2-hexanone.

[106] A 100 mL round-bottom flask, dried with a heat gun and equipped with a stirring rod, rubber septum, nitrogen inlet, and thermocouple probe, was charged with THF (40 mL), iPr2NH (3.0 mL, 21 mmol, 2.1 equiv, 320 mM final concentration). The solution was cooled to 0°C while a solution of nBuLi (1.28 M in hexanes, 15.4 mL, 20.0 mmol, 2.0 equiv, 305 mM final concentration) was added dropwise at a rate such that the internal temperature did not exceed +10°C (~5 min), stirred at 0°C for 10 min, and cooled to -78°C. Acetonitrile (1.10 Petition 870260086668, dated 08 / 25 / 2026, p. 51 / 110 A solution of 41 / 71 mL, 21.0 mmol, 2.1 equiv, 322 mM final concentration) was added dropwise via syringe at a rate such that the internal temperature did not exceed -65°C. The reaction mixture was stirred at -78°C for 15 min, and then a solution of ethyl 5-azido-2,2-dimethylpentanoate (2.04 g, 10.0 mmol, 1.0 equiv, 153 mM final concentration) in THF (4 mL) was added via syringe so that the internal temperature did not exceed -65°C (~3 min). The reaction mixture was stirred at -78°C for 10 min, allowed to warm to 0°C, and stirred at 0°C for 15 min. The reaction mixture was diluted with EtOAc (50 mL) and 5% KHSO4 (50 mL). The aqueous layer was separated and extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with brine (50 mL), dried over MgSO4, filtered, and concentrated.Purification by column chromatography (40 g silica gel cartridge; stepwise gradient elution: 15%, 20%, 30%, 40% EtOAc / hexanes) yielded 1.18 g (6.07 mmol, 59%) of the desired ketone as a pale yellow oil. 1H NMR (CDCl3, 300 MHz) δ 3.61 (d, J=0.4 Hz, 2 H), 3.32 (t, J=6.3 Hz, 2 H), 1.42 - 1.68 (m, 5 H), 1.17 - 1.24 (m, 6 H). (d) 6-azido-1-cyano-3,3-dimethyl-2-hexanol.

[107] A 25 mL round-bottom flask fitted with a stirring bar, rubber septum, and nitrogen inlet was charged with 6-azido-1-cyano-3,3-dimethyl-2-hexanone (1.18 g, 6.08 mmol, 1.0 equiv, 243 mM final concentration) and MeOH (25 mL) and cooled to 0°C. NaBH4 (114 mg, 3.04 mmol, 0.5 equiv, 122 mM final concentration) was added as a solid in a single portion. The reaction mixture was stirred at 0°C for 30 min. The reaction mixture was diluted with EtOAc (50 mL) and 5% aq KHSO4 (50 mL). The aqueous phase was separated and extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with brine (40 mL), dried over MgSO4, filtered, and concentrated. Purification Petition 870260086668, dated 08 / 25 / 2026, page 52 / 110 42 / 71 via column chromatography (40 g silica gel cartridge; step-by-step gradient elution: 20%, 30%, 40%, 50%) EtOAc / hexanes) yielded 1.1 g (5.61 mmol, 97%) of the desired binding alcohol as a pale yellow oil: 1H NMR (CDCl3, 300 MHz) δ 3.68 - 3.79 (m, 1 H), 3.30 (t, J=6.6 Hz, 2 H), 2.39 - 2.60 (m, 2 H), 2.23 - 2.29 (m, 1 H), 1.20 - 1.68 (m, 4 H), 0.93 (s, 3 H), 0.92 (s, 3 H). (e) 6-azido-1-cyano-3,3-dimethyl2-hexyl succinimidyl carbonate

[108] A 50 mL round-bottom flask dried with a heat gun, fitted with a stirring rod, rubber septum, and nitrogen inlet was loaded with NHS (440 mg, 3.83 mmol, 1.5 equiv, 217 mM final concentration), DCM (17 mL), and triphosgene (378 mg, 1.28 mmol, 0.5 equiv, 72 mM final concentration) and cooled to 0°C. The reaction mixture was cooled to 0°C while pyridine (0.68 mL, 8.4 mmol, 3.3 equiv, 48 mM final concentration) was added dropwise via a syringe. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 30 min. A solution of 6-azido-1-cyano-3,3-dimethyl-2-hexanol (500 mg, 2.55 mmol, 1.0 equiv, 144 mM final concentration) in THF (1 mL) was added dropwise using a syringe. The reaction mixture was stirred at room temperature for 1 h, cooled to 0°C, and quenched by the addition of H2O (10 mL). The reaction mixture was further diluted with EtOAc (50 mL) and H2O (50 mL).The organic phase was separated and washed with water (50 mL), 5% aq KHSO4, brine (50 mL), dried over MgSO4, filtered, and concentrated. Purification by column chromatography (40 g silica gel cartridge; stepwise gradient elution: 25%, 30%, 35%, 40% acetone / hexanes) yielded 638 mg (1.89 mmol, 74% yield) of the desired activated ligand as a white solid. Petition 870260086668, dated 08 / 25 / 2026, p. 53 / 110 43 / 712H NMR (CDC13, 300 MHz) δ 4.93 (dd, J=7.l, 5.3 Hz, 1 H), 3.32 (s, 2 H), 2.86 (s, 4 H), 2.71 - 2.79 (m, 2 H), 1.29 - 1.72 (m, 4 H), 1.05 (s., 3 H), 1.04 (s., 3 H). Example 3 Preparation of ligands of formula (I) where Z = protected ketone θ o ♦HN V * ^ADIPEA11 ΓΟ Ft1Me*S°2 '^^COzEt N^ <C°2E------Cl’ EtO ^E(DMFEtOOEtH nBuLiH-HF 2. NaBFL, MeOH OSu

[109] Succinimidyl 2,2-diethoxypropanoate: Concentrated H2SO4 (0.5 mL) was added to an ice-cold mixture of pyruvic acid (8.8 g, 100 mmol) and triethyl orthoformate (40 mL, 240 mmol). The mixture was stirred for 30 min on ice, then diluted with CH2Cl2 and washed twice with cold water followed by brine, dried over MgSCg, filtered, and concentrated to yield 2,2-diethoxypropanoic acid (11.16 g, 69 mmol). This was dissolved in 250 mL of CH2Cl2 and treated with N-hydroxysuccinimide (8.7 g, 76 mmol) followed by dicyclohexylcarbodiimide (15.6 g, 76 mmol) for 2 h. The thick white flow paste was filtered to remove dicyclohexylurea, then passed through a silica buffer. The gel was rinsed with a 1:1 EtOAc / hexane solution, and the combined eluates were concentrated. The residue was crystallized from a hot 20% EtOAc / hexane solution to provide an initial collection of the succinimidyl ester (11.73 g, 45 mmol) as white crystals.Chromatography of the mother liquors in S1O2 (0-60% EtOAc / hexane) followed by crystallization provided an additional product collection, giving a total of 13.0 g of product (50% total pyruvic acid).

[110] 3-[(2,2-diethoxypropanoyl)amino]-2,2-dimethyl propanoate Petition 870260086668, dated 08 / 25 / 2026, page 54 / 110 44 / 71 ethyl; A solution of ethyl 3-amino-2,2-dimethylpropanoate (CombiBlocks; 1.82 g, 10 mmol) and succinimidyl 2,2-diethoxypropanoate (2.6 g, 10 mmol) in 10 mL of DMF was treated with N,N-diisopropylethylamine (3.5 mL, 20 mmol) for 1 hour at room temperature. The mixture was diluted with EtOAc and washed successively with water, 5% KHSO4, sat. aq. NaHCOa, and brine, then dried over MgSO4, filtered, and concentrated. Chromatography on S1O2 (0-70% MTBE / hexane) yielded the ester of the product (2.48 g, 86%) as a colorless oil.

[111] Conversion to succinimidyl carbonate followed the procedures defined for other ligands above. Example 4 Preparation of ligands of formula (I) wherein X = N(R6)CH2C1

[112] Step 1. 4-azido-1-cyano-3,3-dimethyl-2-butyl 4-(N,N-diethylcarboxamido)phenylcarbamate. Pyridine was added to a solution of 4-azido-1-cyano-3,3-dimethyl-2-butanol and triphosgene in T&E. After 15 min, the mixture was filtered and concentrated. The residue was dissolved in CH2Cl2 and treated with N,N-diethyl 4-aminobenzamide and triethylamine. After 1 h, the mixture was diluted with CH2Cl2 and washed with 5% KHSO4, water, and brine, then dried over MgSO4, filtered, and evaporated. The product was crystallized.

[113] Step 2. N-chloromethyl 4-azido-1-cyano-3,3-dimethyl-2-butyl 4-(N,N-diethylcarboxamido)-phenylcarbamate. A mixture Petition 870260086668, dated 08 / 25 / 2026, page 55 / 110 45 / 71 of step 1 carbamate (1 mmol), paraformaldehyde (120 mg), chlorotrimethylsilane (0.5 mL), and 1,2-dichloroethane (4 mL) were sealed in a screw-capped bottle and heated to 50°C for 12 h. After cooling, the mixture was concentrated and the residue was redissolved in 10 mL of MTBE, filtered, and reconcentrated to yield N-chloromethyl carbamate as a colorless oil. Example 5 Preparation of compounds of formula (II) where Z = azide (II) is illustrated in which n = 1, R4 = CHa, Z = Na, and D is octreotide connected through the alpha-amino group of Phe1.

[115] Boc-octreotide. A solution of 58.4 mg / mL of t-butyl succinimidyl carbonate (385 pL) was added to a mixture of octreotide acetate (128 mg) and N,N. [Reference 870260086668, dated 25 / 08 / 2026, page 56 / 110] 46 / 71 diisopropylethylamine (0.2 mL) in 2 mL of amine-free N,N-dimethylformamide. After 4 h, HPLC analysis indicated the presence of 91.6% mono-Boc-octreotide, 3.0% di-Boc-octreotide, and 5.4% octreotide. UV spectrophotometric analysis indicated a total octreotide concentration of 43.5 mM. This solution was used without purification.

[116] General procedure. Compounds of formula (I) were dissolved in 40 mM amine-free DMF. An aliquot of Bococtreotide above (500 μΣ, 21.8 μmol total octreotide) was mixed with the solution of compound of formula (I) (540 μΣ, 21.6 pmol) and kept for 16 h at room temperature. The reaction was diluted in 5 mL of ice-cold 0.1 M acetic acid, and the precipitated ligand-peptide was collected by centrifugation. The granular material was dissolved in 4 mL of methanol and purified by preparative HPLC (C18, 20-80% MeCN / H2O / 0.1% TFA). After drying, the purified material was dissolved in 1 mL of ice-cold 95:5 trifluoroacetic acid / water to remove the Boc group, held for 10 min, then precipitated by adding 10 mL of cold, dry ether.

[117] Compounds of formula (II) prepared according to this method include: Na-[(4-azido-1-((N,N-dimethylamino)sulfonyl)-3,3-dimethyl-2-butoxy)carbonyl]octreotide (n = 1, R1= SO2N(CH3)2, R2= H, R4= CH3, Z = N3, D = octreotide connected through the α-amino group). Yield 23.6 mg (84%), LC-MS shows [M+H]+ = 1295.75 (expected 1295.6).

[118] Na-[(4-azido-1-((N-ethyl-N-methylamino)sulfonyl)-3,3dimethyl-2-butoxy)carbonyl]octreotide (n = 1, R1 = SO2N(CH3)(CH2CH3), R2 = H, R4 = CH3, Z = N3, D = octreotide connected via the α-amino group). Yield 21.6 mg, LC-MS shows [M+H]+ = 1309.75 (expected 1309.6).

[119] Na-[(4-azido-1-((morpholinosulfonyl)-3,3-dimethyl-2butoxy)carbonyl] octreotide (n = 1, R1= SO2N(CH2CH2)2O, R2= H, Petition 870260086668, dated 08 / 25 / 2026, p. 57 / 110 47 / 71 R4 = CH3, Z = N3, D = octreotide connected via the α-amino group). Yield 19.9 mg (84%), LC-MS shows [M+H]+ = 1337.7 (expected 1337.6). [12 0]Να-[ (4-azido-l-( (N,N-bis(2-methoxyethyl) aminosulfonyl) 3,3-dimethyl-2-butoxy) carbonyl]octreotide (n = 1, R1 ii.= SO2N (CH2CH2OCH3) 2, R2= H, R4= CH3, Z = N3, D = octreotide connected through the α-amino group). Yield 35.4 mg, LC-MS shows [M+H]+ = 1383.8 (expected 1383.7).

[121] Na-[(4-azido-l-((isopropylsulfonyl)-3,3-dimethyl-2-butoxy)carbonyl]octreotide (n = 1, R1= SO2CH(CH3)2, R2= H, R4= CH3, Z = N3, D = octreotide connected via the α-amino group). Yield 16.8 mg, LC-MS shows [M+H]+ = 1294.7'' (expected 1294.6).

[122] Na-[(4-azido-l-(1-cyano-3,3-dimethyl-1,2-butoxy)carbonyl]octreotide (n = 1, R1 = CN, R2 = H, R4 = CH3, Z = N3, D = octreotide connected through the α-amino group).

[123] Na-[(4-azido-l-(1-(methylsulfonyl)-3,3-dimethyl-2-butoxy)carbonyl]octreotide (n = 1, R1= SO2CH3, R2= H, R4= CH3, Z = N3, D = octreotide connected through the α-amino group). Na-ligante - [Gin28] -exenatida i. 5% 4MePip, DMF ii. Me2NOzS0 I N3'7Ç 0 OSu / \ I γ / *ίη»28ί dí-* —Z**-NMM. DMF O2S.. FlTIOC ^^^[Gln^Jiexenatida ß Η ... τγλ τιηη υ [Gln28]exenatidaD„ , . . ill. TFA, TIPS, H2O N3Aç Ο Να PG = protection group iv. 5% AcOH, 40°CAH v. C18HPLC

[124] Na-{4-Azido-3,3-dimethyl-1-[(Ν,Νdimethyl)aminosulfonyl]-2-butyloxycarbonyl}-[Gin28] exenatide. In a 25 mL SPE frit column, [Gin28]exenatide (Fmoc α-amine) protected on Rink amide resin (0.63 meq / g substitution, 0.12 mmol peptide / g peptide-resin, 1.00 g peptide-resin, 0.12 mmol peptide) was swollen in 10 mL of DMF for 30 min at room temperature. DMF was removed by syringe filtration using a Luer F / F adapter and a syringe. Petition 870260086668, dated 08 / 25 / 2026, page 58 / 110 48 / 71 of 12 mL, and the swollen resin was treated with 5% 4-methylpiperidine in DMF (2 x 10 mL, 5 min each; then 2 x 10 mL, 20 min each). The unprotected Fmoc resin was then washed with DMF (10 x 10 mL), and supernatants were removed by syringe filtration. The washed resin was suspended in 8.4 mL DMF and treated with 3.6 mL of O'-succinimidyl carbonate of O-{4-azido-3,3-dimethyl-1-[(N,N-dimethyl)aminosulfonyl]-2-butyl} (0.10 M in DMF, 0.36 mmol, 30 mM final concentration) and 4-methylmorpholine (40 pL, 0.36 mmol, 30 mM final concentration). The reaction mixture was stirred using an orbital shaker. After 20 h, the supernatant was removed by syringe filtration, and the resin was successively washed with DMF (5 x 15 mL) and CH2Cl2 (5 x 15 mL). Kaiser's test was negative for free amines in the resin modified by intermediate binder. The resin was then treated with 10 mL of pre-cooled (0°C) TFA:TIPS:H2O 90:5:5 while gently stirring in an orbital shaker.After 2 h, the resin was vacuum filtered and washed with TFA (2 x 1.5 mL). The filtrate was concentrated by rotary evaporation to ~6 mL. The crude peptide ligand was precipitated by dropwise addition of the TFA concentrate to 40 mL of MTBE -20°C in a tared 50 mL Falcon tube. After incubation at -20°C for 10 min, the crude peptide ligand suspension was granulated by centrifugation (3000 x g, 2 min, 4°C), and the supernatant was decanted. The resulting granule was suspended in 40 mL of MTBE -20°C, vortexed to mix, centrifuged, and decanted as above. After drying under high vacuum, the granule was isolated as a whitish solid (575 mg) which was then dissolved in 8 mL of 5% AcOH (~70 mg / mL). After heating in a water bath at 50°C for 45 min, the solution was purified by preparative C18 HPLC to give 13 mL of the title compound (3.33 mM, 43 pmol per A280) as an aqueous solution. Lyophilization yielded 235 mg of a white solid. HPLC C18 purity determined at 280 nm: 90.0% (RV = 11.47 mL) Petition 870260086668, dated 08 / 25 / 2026, p. 59 / 110 49 / 71 Mav: 4476.9 calculated; 4476 observed Example 6 Preparation of compounds of formula (II) where Z = ketone

[125] The preparation of compounds of formula (II) in which Z = ketone is illustrated in an example in which n = 1, R1= SCgNÍCHaH, R2 = H, each R4 = CHa, Z = NH-pyruvoyl, and D = Nabound octreotide.

[126] A 250 mM solution of t-butyl succinimidyl carbonate in DMF (440 pL) was added to a mixture of octreotide acetate (128 mg) and N,N-diisopropylethylamine (0.2 mL) in 2 mL of amine-free DMF. After 1 h, HPLC analysis indicated the presence of 90% mono-Boc-octreotide, 2.5% di-Bococtreotide, and 7% octreotide. A solution of 4-(2-diethoxypropionamido)-1-((N,N-dimethylamino)sulfonyl)-3,3-dimethyl-2-butyl succinimidyl carbonate (Example 3; 54 mg) in 100 pL of DMF was added. The mixture was kept at room temperature for 16 h, then diluted with EtOAc and washed with 5% KHSO4 followed by brine. After drying over Na2SO4, the mixture was filtered and concentrated to produce the Petition 870260086668, dated 08 / 25 / 2026, pp. 60 / 110 50 / 71 intermediate completely protected as a foam. This was dissolved in 1 mL of CH3CN and treated with 1 mL of 2 N HCl at 50°C for 30 min. The solution was cooled to room temperature, diluted with 2 mL of water and carefully added to 5 mL of NaHCOa 1 mL. The precipitated product was collected by centrifugation, washed with water and dichloromethane, and dissolved in 5 mL of methanol. Example 7 Preparation of drug-ligand of formula (II) where Y = N (R6) CH2

[127] A solution of SN-38 (100 mg) in 10 mL of DMF / THF 1:1 was cooled on ice and treated dropwise with 1 M potassium tert-butoxide (0.26 mL, 1 Eq). The resulting orange suspension was stirred for 30 min, then a solution of the N(chloromethyl) carbamate ligand (Example 4, 1 mmol) in 1 mL of THF was added. The orange color gradually faded and the suspension cleared. The mixture was quenched with 10% aqueous citric acid, in Petition 870260086668, dated 08 / 25 / 2026, pp. 61 / 110 51 / 71 followed by extraction with ethyl acetate. The organic extract was washed with water and brine, then dried over MgSO4, filtered, and evaporated. Purification by chromatography on SiO2 using a 0-100% acetone gradient in hexane yielded the drug ligand of formula (II) where n = 1, R1 = CN, R2 = H, each R4 = Me, D = SN-38, Y = N(R6)CH2 (R6 = 4-(N,N-diethylcarboxamidophenyl)), and Z = azide.

[128] The corresponding compound in which Z = amine was prepared as follows. A solution of the compound in which Z = azide in THF was added to a mixture of 1 M trimethylphosphine in THF and acetic acid. After gas evolution had ceased, water was added and the mixture was stirred for 1 h before concentrating to dryness. The residue was divided between water and ethyl acetate, and the aqueous phase was collected and dried. Final purification by preparative HPLC used a gradient of 0-100% acetonitrile / water / 0.1% TFA. Example 8 Formation of conjugates of formula (III) where M is soluble PEG and Z* = 1,2,3-triazole

[129] A mixture of 20-kDa 4-armed PEG-tetra(cyclo-octine) (prepared according to Example 14 below, prepolymer B) and the drug ligand in which Z = azide of Example 5 in acetonitrile was maintained at 50°C for 16 h. Dialysis (12-kDa SpectraPor 2) against water followed by methanol yielded the conjugate of formula (III) where M is soluble 4-armed PEG and Z* is 1,2,3-triazole. Example 9 Formation of conjugates of formula (III) where M is soluble PEG and Z* = oxime

[130] 4-armed 20-kDa PEG-tetra(aminooxyacetamide) was prepared by reacting 4-armed 20-kDa PEG-tetraamine (100 mg, NOF America) with excess (Boc-aminooxy)acetic acid in the presence of HATU and N,N-diisopropylethylamine in DMF. After 1 h, the Petition 870260086668, dated 08 / 25 / 2026, p. 62 / 110 52 / 71 PEG was precipitated by slow addition to stirred MTBE, collected by centrifugation, and dried under vacuum. This was dissolved in 2 mL of CH2CK / CF3CO2H 1:1, held for 1 h, and evaporated to dryness. The residue was dissolved in 2 mL of THF and the product was precipitated by slow addition to stirred MTBE, collected by centrifugation, and dried under vacuum.

[131] A mixture of 20-kDa 4-armed PEG-tetra(aminooxyacetamide) and the drug ligand wherein Z = ketone of example 6 in DMSO / 0.1 M acetic acid 1:1 was maintained at 50°C for 16 h. Dialysis (12-kDa SpectraPor 2) against water followed by methanol yielded the purified conjugate of formula (III) wherein M is soluble 4-armed PEG and Z* is oxime. Example 10 Formation of conjugates of formula (III) where M is soluble PEG and Z* = carboxamide

[132] A mixture of 20-kDa 4-armed PEG-tetra(succinimidyl ester) (JenKem), N,N-diisopropylethylamine, and the drug ligand in which Z = amine of example 7 in THF was stirred for 1 h. Dialysis (12-kDa SpectraPor 2) against water followed by methanol yielded purified formula conjugate (III) in which M is soluble 4-armed PEG and Z* is carboxamide. Example 11 Formation of conjugates of formula (III) where M is an insoluble degradable PEG microsphere

[133] A suspension of PEG microspheres (100 mL) of formula (IV) where P1 and P2 are both 10-kDa 4-armed PEGs, Z* = 1,2,3-triazole, n = 1, each R4 = CH3, R1 = SO2N(CH3)2, R2 = H, and W = CH((CH2)4NH2)C(=O)NH (i.e., x = 0, y = 4, z = 0, B = NH2, and C* = carboxamide) (prepared according to example 14 below) was activated by reaction with 4-cyclooctinyl succinimidyl carbonate and N,N-diisopropylethylamine in acetonitrile. The resulting hydrogel comprising a multiplicity of reactive Z' = cyclooctinyl groups was then suspended in 50 Petition 870260086668, dated 08 / 25 / 2026, p. 63 / 110 53 / 71 mM acetate buffer, pH 5, and reacted with a drug-binding solution of formula (II) wherein Z = azide, n = 1, each R4 = CH3, R1 = SO2N(CH3)2, R2 = H, and D = HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSSGAP-NH2 (exenatide-[N28Q] (example 5) . After 48 h at 50°C, the microspheres were washed extensively with acetate buffer to remove unconjugated peptide. Analysis indicated that the fluid paste with packed microspheres contained 2.1 μmol of bound peptide / mL fluid paste. Example 12 Release kinetics

[134] Conjugates were dissolved in 100 mM buffer at 0.25-2 mM and maintained at 37°C in a thermostated HPLC autosampler. Samples (5-10 pL) were periodically removed and injected into the HPLC (Phenomenex Jupiter 5um 4.6x150 mm C18 reverse phase) and eluted with a linear gradient from 0 to 100% MeCN / H2O / 0.1% TFA at 1 mL / min. Peaks were detected at 280 nm (peptides) or 350 nm (dinitrophenyl-Lys) and integrated to provide peak areas for the conjugates and released peptides. Drug-releasing extensions were calculated as (area of ​​released drug) / [(area of ​​released drug)+(area of ​​conjugate)]. Octreotides linked to the α-amine as described in example 5 above were conjugated to 20-kDa-cyclooctine MeO-PEG as described in example 8. Half-lives for release at pH 7.4 were calculated from the results obtained at a given pH using the equation t1 / 2(pH 7.4) = ln(2) · 10 <X-7,4) / kobs Table 1 R1 PH Temp (°C) kobs (h-1) Calculated t1 / 2 (h) for pH 7.4, 37°C CN 9.29 37 0.1283 419 CN 9.29 38 0.1616 380 a Petition 870260086668, dated 08 / 25 / 2026, page 64 / 110 54 / 71 SO2Me 9.29 38 0.4798 128 to SO2iPr 9.29 38 0.3985 154 to SO2NMe2 9.29 37 0.08548 629 SO2NMe2 9.40 37 0.09602 722 SO2N(Et)Me 9.29 37 0. 043 1251 SO2 (morpholino) 9.29 38 0.3148 195 a SO2(4methylpiperidinyl) 9.29 37 0.04896 1099 SO2(4methylpiperidinyl) 9.29 38 0.06448 954 a SO2(4methylpiperidinyl) 9.40 37 0.05947 1166 Table 1. Release kinetics of α-linked octreotide from soluble PEG conjugates in borate buffer with various pH indices and temperatures. ti / 2, 37°C = (ti / 2, 38°C)*1.143 (See Arrhenius equation in Santi PNAS 2012, SI). In all cases, n = 1, R2 = H, each R4 = Me, Z = N3, Y is absent, and D = α-linked octreotide. Example 13 Aza-Michael reaction kinetics

[135] Direct reaction kinetics: In each of three 1.5 mL glass HPLC vials, a 5 mM solution of either standard, β-methyl, or gem dimethyl vinyl sulfone (0.1 mL, 0.5 pmol, 0.5 mM final concentration) in DMSO was added to 0.9 mL of pre-warmed glycine cleavage buffer A, B, or C. The vials were kept in a heated HPLC autosampler (37°C), and the aza-Michael reactions were monitored periodically by C18 HPLC. Cleavage buffer A: 1.1 M glycine (1.0 M final concentration), 0.11 M HEPES, pH 7.4 at 37°C. Cleavage buffer B: 1.1 M glycine (1.0 M final concentration), 0.11 M bicine, pH 8.4 at 37°C. Petition 870260086668, dated 08 / 25 / 2026, page 65 / 110 55 / 71 Cleavage buffer C: 0.11 M glycine (0.10 M final concentration), pH 9.5 at 37°C.

[136] Keq was calculated using the following equations: Keq = Keq app / [Gly] Keq app = [GA]eq / [VS]eq = plateau / (0.5 mM — plateau) [Gly] = glycine concentration in M [GA] = glycine adduct concentration in mM [VS] = vinyl sulfone concentration in mM Plateau (mM) determined in Prisma.

[137] The two unknowns, kf (association) and kr (dissociation), are calculated from the two equations below with kobs determined by Prisma fitting and Keq app defined above: kobs = kf[Gly] + kr kf[Gly] / kr = Keq app.

[138] Reverse reaction kinetics: The rate of the dissociative reverse-Michael reaction (Figure 2.3A) was measured directly from isolated glycine adducts. Each purified glycine adduct was diluted in HEPES buffer, pH 7.4 at 37°C in the absence of added glycine. The concentration of the starting glycine adduct was plotted against time, and each curve was fitted to a first-order decay in Prisma (Figure 2.3B). For each reaction, the calculated infinite value was <1 μM, indicating that the reactions proceeded to termination, thus kr is essentially equivalent to kobs. For each of three 0.3 mL conical plastic HPLC flasks, a 0.7–3.8 mM solution of either standard, β-methyl, or gem adduct dimethyl sulfo-DIBO glycine (11 nmol, 50 μM final concentration) in DMSO was added to 0.2 mL of pre-warmed 0.1 M HEPES, pH 7.0, containing sufficient water to adjust the final volume to 0.22 mL.The reaction flasks were kept in a heated HPLC autosampler (37°C), and the aza-Michael retroreaction reactions were periodically monitored by HPLC C18. The concentration of the starting glycine adduct [GA] in μM was calculated using the equation below. Petition 870260086668, dated 08 / 25 / 2026, page 66 / 110 56 / 71 plotted on a time-versus-time graph using Prisma: [GA] = ga / (ga+vs)* 50 μM [GA] = glycine adduct concentration in μM ga = integrated HPLC peak area of ​​glycine adduct (254 nm) vs = integrated HPLC peak area of ​​vinyl sulfone (254 nm) μM = [GA] ie maximum possible [VS] kr(dissociation) determined by fitting the data to a first-order decay in Prisma. Example 14 Preparation of degradable PEG hydrogels BC I| CB Petition 870260086668, dated 08 / 25 / 2026, page 67 / 110 57 / 71

[139] Hydrogels of the invention are prepared by polymerization of two prepolymers comprising C and C' groups which react to form a linking functional group, C*. The prepolymer linkage with one of C or C' further comprises a cleavable linker introduced by a reaction with a molecule of formula (I), in order to introduce the cleavable linker into each crosslink of the hydrogel.

[140] In one embodiment, a first prepolymer comprises a 4-arm PEG in which each arm is terminated with an adapter unit having two mutually non-reactive (orthogonal) functional groups B and C. B and C may initially be present in protected form to allow selective chemistry in subsequent steps. In certain embodiments, the adapter unit is an amino acid derivative, particularly lysine, cysteine, aspartate, or glutamate, including derivatives in which the alpha-amine group has been converted to an azide, for example, 2-azidoglutaric acid monoesters. The adapter unit is connected to each first prepolymer arm via a connecting functional group A*, formed by the condensation of a functional group A in each prepolymer arm with a cognate functional group A' in the adapter unit.A second prepolymer comprises a 4-arm PEG in which each arm is terminated with a C' functional group having complementary reactivity with the C group of the first prepolymer, such that crosslinking between the two prepolymers occurs when C and C' react to form C*.

[141] As an illustrative example, a first prepolymer was prepared as follows. H-Lys(Boc)-OH was acylated with a ligand of formula (I) wherein Z = azide to give an adapter unit wherein A = COOH, B = NH2 Boc-protected, and C = azide. This was coupled to 4-armed, 20-kDa PEG-tetraamine, and the Boc group was removed to provide a first prepolymer wherein A* = amide, B = NH2, and C = azide and wherein a cleavable ligand of formula (I) is incorporated into the linkage between each arm and group. Petition 870260086668, dated 08 / 25 / 2026, page 68 / 110 58 / 71 C of the first prepolymer. The corresponding second prepolymer was prepared by acylation of 20 kDa, 4-armed PEG-tetraamine with 5-cyclooctinyl succinimidyl carbonate to give a second prepolymer wherein C' = cyclooctyne. After mixing the first and second prepolymers, the reaction of the C = azide and C' = cyclooctyne groups forms corresponding triazole groups and thus crosslinks the two prepolymers into a three-dimensional network, with each crosslink comprising a cleavage linker resulting from the incorporation of the compound of formula (I), and wherein each node resulting from the incorporation of a first prepolymer comprises a remaining functional group B = NH2 that can be derivatized for the attachment of additional linkers, drugs, fluorophores, metal chelators, and the like. Na-Boc-N£-{4-azido-3,3-dimethyl-1 - [(N^N-dimetH)aminosulfonyl]-2-butyloxycarbonyl}-Lys-OH

[142] A solution of Boc-Lis-OH (2.96 g, 12.0 mmol) in 28 mL of H2O was successively treated with 1 M aq NaOH (12.0 mL, 12.0 mmol), 1 M aq NaHCO3 (10.0 mL, 10.0 mmol), and a solution of O-{4-azido-3,3-dimethyl-1-[(N,N-dimethyl)aminosulfonyl]-2-butyl} -O'succinimidyl carbonate (3.91 g, 10.0 mmol, 0.1 M final concentration) in 50 mL of MeCN. After stirring for 2 hours Petition 870260086668, dated 08 / 25 / 2026, pp. 69 / 110 At room temperature, the reaction was judged to be complete by HPLC C18 (ELSD). The reaction was quenched with 30 mL of 1 M KHSO4 (aq). The mixture was divided between 500 mL of EtOAc:H2O 1:1. The aqueous phase was extracted with 100 mL of EtOAc. The combined organic phase was washed with H2O and brine (100 mL each), then dried over MgSO4, filtered, and concentrated by rotary evaporation to give the crude titer compound (5.22 g, 9.99 mmol, 99.9% crude yield) as a white foam. HPLC C18, purity foi determined by ELSD: 99.1% (RV = 9.29 mL). LC-MS (m / z): calculated, 521.2; observed, 521.3 [MH]-. (2) Na-Boc-N£-{4-azido-3,3-dimethyl-1 - [ (Ν,Ν-dimethyl)aminosulfonyl]-2-butyloxycarbonyl}-Lys-OSu.

[143] Dicyclohexylcarbodiimide (60% in xylenes, 2.6 M, 4.90 mL, 12.7 mmol) was added to a solution of Naα-Boc-Neε-{4azido-3,3-dimethyl-1-[(N,N-dimethyl)aminosulfonyl]-2-butyloxycarbonyl}-Lys-OH (5.11 g, 9.79 mmol, 0.1 M final concentration) and N-hydroxysuccinimide (1.46 g, 12.7 mmol) in 98 mL of CH2Cl2. The reaction suspension was stirred at room temperature and monitored by HPLC C18 (ELSD). After 2.5 h, the reaction mixture was filtered and the filtrate was loaded onto a SiliaSep 120 g column. The product was eluted with a stepwise gradient of acetone in hexane (0%, 20%, 30%, 40%, 50%, 60%, 240 mL each). Fractions containing the cleared product were combined and concentrated to give the title compound (4.95 g, 7.99 mmol, 81.6% yield) as a white foam. HPLC C18, purity was determined by ELSD: 99.7% (RV = 10.23 mL). LC-MS (m / z): calculated, 520.2; observed, 520.2 [M+H-Boc]+. (3) (Na-Boc-N£- {4-azido-3,3-dimethyl-1 - [ (Ν,Ν-dimetH) aminosulfonyl ] -2-butyloxycarbonyl} -Lys) 4-PEG20kDa.

[144] PEG20kDa-(NH)4 (20.08 g, 0.9996 mmol, 3.998 mmol NH2, 0.02 M NH2 final concentration) was dissolved in 145 mL of MeCN. A solution of Na-Boc-Ne-{4-azido-3,3-dimethyl-1-[(N,N-dimethyl) Petition 870260086668, dated 08 / 25 / 2026, pp. 70 / 110 60 / 71 aminosulfonyl]-2-butyloxycarbonyl}-Lys-OSu (2.976 g, 4.798 mmol) in 50 mL of MeCN was added. The reaction was stirred at room temperature and analyzed by HPLC C18 (ELSD). The starting material was converted into a single product peak through three slower elution intermediate peaks. After 1 h, Ac2O (0.37 mL, 4.0 mmol) was added. The reaction mixture was stirred for another 30 min, then concentrated to ~50 mL by rotary evaporation. The reaction concentrate was added to 400 mL of stirred MTBE. The mixture was stirred at room temperature for 30 min, then decanted. MTBE (400 mL) was added to the wet solid, and the suspension was stirred for 5 min and decanted. The solid was transferred to a vacuum filter and washed / crushed with 3 x 100 mL of MTBE. After drying on the filter for 10 min, the solid was transferred to a 250 mL HDPE storage bottle.Residual volatiles were removed under high vacuum until the weight stabilized to provide the title compound (21.23 g, 0.9602 mmol, 96.1% yield) as a white solid. HPLC C18, purity was determined by ELSD: 89.1% (RV = 10.38 mL) with an impurity of 10.6% (RV = 10.08 mL). (4) (Νε-{4-azido-3,3-dimethyl-1 - [ (Ν,Ν-dimethyl)aminosulfonyl] -2-butyloxycarbonyl}-Lys)4-PEG20kDa.

[145] (NE-{4-azido-3,3-dimethyl-1-[(N,N-dimethyl)aminosulfonyl]-2-butyloxycarbonyl}-Lys)4-PEG20kDa (19.00 g, A 0.8594 mmol, 3.438 mmol Boc, final concentration 0.02 M Boc) solution was dissolved in 86 mL of 1,4-dioxane. After stirring for 5 min to completely dissolve the PEG, 4 M HCl in dioxane (86 mL, 344 mmol HCl) was added. The reaction was stirred at room temperature and analyzed by HPLC C18 (ELSD). The starting material was converted into a single product peak through three intermediate peaks of faster elution. After 2 h, the reaction mixture was concentrated to ~40 mL. THF (10 mL) was added to the concentrate, and the solution was concentrated again to ~40 mL. Petition 870260086668, dated 08 / 25 / 2026, pp. 71 / 110 61 / 71 mL. The viscous oil was poured into 400 mL of stirred Et2O. After stirring at room temperature for 20 min, the supernatant was decanted from the precipitate. The wet solid was transferred to a vacuum filter with the aid of 200 mL of Et2O and washed with Et2O (3 x 75 mL). The solid was dried on the filter for 10 min, then transferred to a 250 mL HDPE storage bottle. Residual volatiles were removed under high vacuum overnight to give the title compound (17.52 g, 0.8019 mmol, 93.3% yield @ 4 HCl) as a white solid. HPLC C18, purity was determined by ELSD: 99.2% (RV = 9.34 mL). Prepolymer B where C' = cyclooctinyl.

[146] A 4-mL screw-capped vial was loaded with PEG20kDa-[NH2]4 (SunBright PTE-200PA; 150 mg, 7.6 μmol PEG, 30.2 μmol NH2, 1.0 equiv, 20 mM final amine concentration), MeCN (1.5 mL), and iPr2NEt (7 pL, 40 pmol, 1.3 equiv, 27 mM final concentration). A cyclooctine solution with activated ester (39 pmol, 1.3 equiv, 27 mM final concentration) was added and the reaction mixture was stirred at room temperature. Reactions were monitored by HPLC C18 (20-80% B for 11 min) by ELSD. When complete, Ac2O (3 pL, 30 pmol, 1 equiv NH2 starting) was added to the reaction mixture and the mixture was stirred for 30 min. The reaction mixture was then concentrated into a thick oil and suspended in MTBE (20 mL). The resulting suspension was vigorously stirred for 10 min. The resulting solids were triturated three times with MTBE (20 mL) by vigorous mixing, granulated in a centrifuge (2800 rpm, 4°C, 10 min), and the supernatant removed by pipette.The resulting solids were dried under vacuum at room temperature for no more than 30 min. Stock solutions were prepared in 20 mM NaOAc (pH 5) with a target amine concentration of 20 mM. Cyclooctine concentration was then verified by treatment with PEG7-N3 (2 equiv) and back-titration of the unreacted PEG7-N3 with DBCO-CO2H.

[147] Macromanomers prepared using this procedure Petition 870260086668, dated 08 / 25 / 2026, p. 72 / 110 62 / 71 include those in which the cyclooctine group is MFCO, 5-hydroxycyclooctine, 3-hydroxycyclooctine, BCN, DIBO, 3-(carboximethoxy)cyclooctine, and 3-(2-hydroxyethoxy)cyclooctine, prepared using MFCO pentafluorophenyl ester, 5-((4-nitrophenoxycarbonyl)oxy)cyclooctine, 3-(4-nitrophenoxycarbonyl)oxycyclooctine, succinimidyl hydroxycarbonate BCN, succinimidyl 4-nitrophenyl carbonate ester DIBO, 3-(carboximethoxy)cyclooctine and 3-(hydroxyethoxy)cyclooctine 4-nitrophenyl carbonate, respectively.

[148] Preparation of hydrogel microspheres. Hydrogel microspheres were prepared and activated as described in Schneider et al. (2016) Bioconjugate Chemistry 27: 1210-15. Example 15 Compound of formula (II) in which Z = N3, n = 1, R1 = (4methylphenyl)SO2, R2 = H, each R4 = Me, Y = absent, and D = insulin lispro fixed via LysB28

[149] As an alternative to the preparation of compounds of formula (II) by solid-phase peptide synthesis (see Example 5), compounds of formula (II) in which D is a peptide can be formed by reacting the pre-formed peptide with an activated ligand of formula (I) under conditions in which at least one amine group in the peptide is free for reaction. When the peptide comprises both an N-terminal alpha-amine and one or more epsilon-amine lysines, preferential ligand attachment to an epsilon-amine lysine can be achieved by carrying out the reaction at high pH or in an organic solvent in the presence of excess tertiary amine.

[150] A 10 mL vial of Humalog (100 U / mL) was adjusted to pH 5.4 using 0.1 N HCl, and the resulting precipitate was collected by centrifugation and the granule was washed with 2 x 15 mL of ethanol, 1 x 15 mL of methyl tert-butyl ether (MTBE), and dried under vacuum. Dried insulin lispro (35 mg, 6 μmol) was dissolved in 3 mL of dimethylformamide (DMF) and 30 μL (170 μmol) of N,N-diisopropylethylamine. Petition 870260086668, dated 08 / 25 / 2026, page 73 / 110 63 / 71 (DIPEA). A 100 mM solution of 4-azido-3,3-dimethyl-1-(4-methylphenylsulfonyl)-2-butyl succinimidyl carbonate in DMF (84 pL, 8.4 pmol) was added and the mixture was stirred at room temperature for 1 h. The mixture was evaporated to dryness under vacuum, and the residue was dissolved in 10 mL of water / acetonitrile / 0.1% trifluoroacetic acid 3:1. Purification by preparative HPLC using a Jupiter 5um 300A C18 21.2x150 mm reversed-phase column using a 30-50% acetonitrile / water / 0.1% TFA gradient for 20 min at 15 mL / min yielded pure lispro-ligand azido where the ligand is fixed via Lys28 chain εamine B (compound of formula (II) where Z = N3, n = 1, R1 = (4-methylphenyl)SO2, R2 = H, each R3 = Me, Y = absent, and D = insulin lispro fixed via LysB28).

[151] Ligating peptides similar to formula (II) were prepared using the teduglutide peptide, [Gly2]GLP-2. Example 16 PEG conjugate releasing insulin lispro Compound of formula (III) wherein M = 20-kDa MeO-PEG, Z* = triazole, n = 1, R1 = (4-methylphenyl)SO2, R2 = H, each R4 = Me, Y = absent, D = insulin lispro fixed via LysB28, eq = 1.

[152] A solution of methoxy-PEG-amine 20-kDa (BroadPharm, 100 mg, 5 pmol), DIPEA (3 pL, 17 pmol), and (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethyl succinimidyl carbonate (BCN-OSu, Sigma, 2 mg, 7 pmol) in 1 mL of acetonitrile was stirred at room temperature for 1 h, then evaporated to dryness. The residue was dissolved in 1 mL of THF and the solution added to 10 mL of MTBE with stirring. The PEG-cyclooctine precipitate was collected, washed with MTBE, and dried under vacuum.

[153] A mixture of the azido-insulin-binding lispro of example 15 (1.1 pmol) and PEG-cyclooctine (20 mg, 1 pmol) in 1 mL isopropanol:citrate buffer 1:1, pH 4, was kept at room temperature for 4 h, then dialyzed against water followed by methanol using a 12-14 kDa shear membrane. The product Petition 870260086668, dated 08 / 25 / 2026, pp. 74 / 110 64 / 71 dialysate was evaporated to dryness to provide the compound of formula (III) wherein M = 20-kDa MeO-PEG, Z* = triazole, n = 1, R1 = (4-methylphenyl)SO2, R2 = H, Y = absent, D = insulin lispro fixed via LysB28, eq = 1.

[154] When dissolved in 0.1 M borate buffer, pH 9.4, 37°C, this conjugate released free insulin lispro with t1 / 2 = 2.08 h. Extrapolate to t1 / 2 = 2.08 h pH 7.4, 37°C.

[155] The cognate conjugate in which R1= phenyl-SO2 was prepared similarly, and released free lispro insulin with t1 / 2 = 0.8 h when dissolved in 0.1 M borate buffer, pH 9.4, 37°C. This extrapolates to t1 / 2 = 80 h at pH 7.4, 37°C. Example 17 Hydrogel comprising releasable lispro insulin

[156] The azide-binding insulin lispro of example 15 was attached to the degradable PEG hydrogel of example 14 to provide a slow-release insulin lispro depot. For the PEGhydrogel, prepolymer A was (Na-Boc-Νε-{4-Azido-3,3-dimethyl-1[(N,N-dimethyl)aminosulfonyl]-2-butyloxycarbonyl}-Lys)4-PEG10kDa, and prepolymer B was ((4-cycloctynylaoxy-carbonyl)amino)4PEG10kDa, which provided a PEG-hydrogel of formula (IV) wherein and P2 were both 10-kDa 4-arm poly(ethylene glycol)ols, Z* = triazole, n = 1, R1 = (N,N-dimethylamino)SO2, R2 = H, each R4 = CH3, and W = (CH2)x-CH[(CH2)yB]-(CH2)zC wherein x = 4, y = 0, z = 0, B = NH2, and C* = carboxamide. This PEG hydrogel was formed as microspheres as previously described in PCT Publication WO2019 / 152672, which is incorporated by reference.

[157] A packed suspension of these hydrogel microspheres (B = NH2) in acetonitrile (3.5 g containing 10.8 μmol of NH2 by TNBS assay) was activated for ligand-drug binding by reaction with BCN-OSu (16.2 μmol) and triethylamine (43.1 μmol) for 4.5 h. Acetic anhydride (10.8 μmol) was added to any unreacted amine groups, and after 2 h the flowable paste was washed 5 times with 11 mL of acetonitrile followed by 5 times with 11 mL Petition 870260086668, dated 08 / 25 / 2026, pp. 75 / 110 65 / 71 of drug solvent loading (100 mM citrate in iPrOH:H2O 1:1 at pH 3.0). The final packed flow paste was ~5.6 mL containing 7.3 μmol of cyclooctine (B = [(1R,8S,9s)-bicyclo[6.1.0]non-4yn-9-ylmethoxycarbonyl]amino).

[158] A mixture of activated hydrogel microspheres and azido-insulin-ligand lispro in drug-solvent loading was gently mixed for 24 h, then the suspension was repeatedly washed with reaction buffer to remove any unreacted azido-insulin-ligand lispro and reaction byproducts. The final microsphere preparation comprised 1.5 μmol / mL insulin lispro, which was released with t1 / 2 = 350 h pH 7.4, 37°C. Example 18 Hydrogel comprising releasable exenatide

[159] The degradable hydrogel of example 14 wherein P1 and P2 were both 4-armed 10-kDa poly(ethylene glycols), Z* = triazole, n = 1, R1 = (N,N-dimethylamino)SO2, R2 = H, each R4 = CH3, and W = (CH2)x-CH[(CH2)yB]-(CH2)zC wherein x = 4, y = 0, z = 0, B = NH2, and C* = carboxamide that was activated by reaction with cyclooctinyl succinimidyl carbonate (5HCO-OSu), then the azido-ligand exenatide[N28Q] of example 5 was ligated. A packed starch microsphere flow paste (1.2 mL) in MeCN containing 10.3 μmol of amine was combined with pure triethylamine (41.1 pmol) and 5HCO-NHS (15.4 pmol). The reaction was continuously mixed for 18 h and a qualitative TNBS test confirmed the loading of the amines (described in the general methods). Acetic anhydride was added (1 eq, 10.3 pmol) to cover any remaining free amines and after a reaction of 2 h the flow paste was washed 5 times with 6 mL of acetonitrile. The final packed flow paste was 1.4 mL containing 10.3 pmol 5HCO-NHS.Two tared 10 mL syringes were filled with ~1 g of 5HCO₃-fluid paste of microspheres in MeCN, containing ~9 pmol 5HCO₃. The fluid pastes were washed 4 times with 6.5 mL of reaction solvent (100 mM citrate in DMSO:H₂O 1:1 at pH 3.0). The N₃-peptide was added to the paste. Petition 870260086668, dated 08 / 25 / 2026, pp. 76 / 110 66 / 71 fluid packed at 1.2 equivalents for 5HCO (11 μmol N3) and incubated at 37C for 18 hours with shaking.

[160] The loaded microspheres were washed 5 times with 6.5 mL of reaction solvent (OD280 of the final wash was below detection) followed by 3 washes with isotonic acetate buffer (10 mM sodium acetate, 143 mM NaCl, 0.05% polysorbate 20 (w / v) pH 5.0) and 2 times with isotonic acetate buffer containing 0.8% Na carboxymethyl cellulose. The payload concentration and loaded fraction were determined by solubilizing ~50 μL of the packed fluid paste (~50 mg) in 9 volumes (~450 μΣ) of 50 mM NaOH for one hour at room temperature. The payload content was determined by absorbance at 280 nm for [Gln28]exenatide (E= 5500 M-1cm-1). A PEG assay was performed on the same NaOH solubilized samples to measure the PEG concentration for each construct and determine the charge of the fraction compared to the peptide concentration.

[161] Samples of the loaded microspheres (~50 mg) were placed in 1.5 screw-cap microcentrifuge tubes and the release / degelling kinetics reaction was initiated by adding 19 volumes (0.95 mL) of 100 mM sodium borate buffer, pH 9.4 at 37°C. In order to capture as many time points as possible, two reactions for each conjugate were initiated 18 hours apart. The reactions at 37°C were incubated in a stirred water bath. At t=0 and at various points in time, the fluid pastes of microspheres were granulated to 20,000 x g, the visual presence or absence of a microsphere granule was observed, 20 μΣ of the reaction supernatant were removed and quenched by the addition of 4 μΣ of 4M acetic acid, and the samples were stored at -20°C. The concentration of exenatide[N28Q] in the reaction supernatant was determined by absorbance at 280 nm on a Nanodrop UV-Vis spectrometer.The state of the microspheres was also visually observed at each point in time (solid / present or dissolved / disappeared). The A280. Petition 870260086668, dated 08 / 25 / 2026, page 77 / 110 67 / 71 of the supernatant time points were plotted and fitted to a single exponential to determine the release rate for each peptide. A PEG assay was performed on the supernatant samples to measure the soluble PEG concentration at each time point to generate a reverse solubilization / gelation curve. The microsphere assay showed a peptide content of 5.19 μmol / mL, corresponding to 95% loading of available B sites. At pH 9.4, 37°C, these hydrogel microspheres released exenatide[N28Q] with ti / 2 = 17.5 h, and dissolved with a degelation time of 32 h.

[162] A similar exenatide-releasing hydrogel is prepared by replacing the cyclooctinyl succinimidyl carbonate used in the activation step with BCN-OSu, as illustrated in example 17.

[163] These exenatide-releasing hydrogel microspheres have the general formula shown in Figure 7, wherein P1 and P2 are each 4-armed poly(ethylene glycol)ols, Z* is triazole, C* is carboxamide, B* is triazole, and LD is the residue of a drug ligand of formula (II). Example 19 Preparation of oligonucleotide ligands

[164] Conjugates of a TLR9 receptor agonist of the CpG phosphorothioate oligonucleotide were made as below. 5'-CpG-3'-NH2 5'-T*C*G*A*A*C*G*T*T*C*G*A*A*C*G*T*T*C*G*A*A*C*G*T*T*C*G*A*A*T „ AO °:k Ό Ο γ Ο 'ΌΐΗ, *=phosphorothioate OH Petition 870260086668, dated 08 / 25 / 2026, pp. 78 / 110 68 / 71 Glycine θ NaOH, NaHCO3 DCC, NHS CH2CI2 Stage 1 Stage 2 O x x-\ x\ x~v ,3'-CpG-5' OH 0.1 M HEPES, pH 7.4 °C Step 3

[165] Step 1. N-[4-azido-3,3-dimethyl-1-(4-chlorophenyl)sulfonyl-2-butyloxycarbonyl]-Gly-OH. A solution of glycine (18 mg, 0.24 mmol) in 0.56 mL of H2O was successively treated with 1 M aq NaOH (0.24 mL, 0.24 mmol), 1 M aq NaHCO3 (0.20 mL, 0.20 mmol), and a solution of 4-azido-3,3-dimethyl-1-(4-chlorophenyl)sulfonyl-2-butyl succinimidyl carbonate (92 mg, 0.20 mmol, 0.1 M final concentration) in 1.0 mL of MeCN. After stirring for 45 min at room temperature, the reaction was judged to be complete by HPLC C18 (ELSD). The reaction was quenched with 5 mL of 1 M aq KHSO4, then divided between 20 mL of EtOAc:H2O1:1. The aqueous phase was extracted with 5 mL of EtOAc. The combined organic phase was washed with H2O and brine (10 mL each), then dried over MgSO4, filtered, and concentrated by rotary evaporation to give the crude titer compound (85 mg, 0.20 mmol, quantitative crude yield) as a turbid film. HPLC C18, purity was determined by ELSD: 98.6% (RV = 9.42 mL).nLC-MS (m / z): calculated for 35Cl, 417.1; observed, 417.0 [MH]-; calculated for 37Cl, 419.1; observed, 419.1 [MH]-.

[166] Step 2. N-[4-Azido-3,3-dimethyl-1-(4-chlorophenyl)sulfonyl-2-butyloxycarbonyl]-Gly-OSu.Dicyclohexylcarbodiimide (60% in xylenes, 2.6 M, 100 pL, 0.26 mmol) was added to a solution of N-[4-azido-3,3-dimethyl-1-(4-chlorophenyl)sulfonyl-2-butyloxycarbonyl]-Gly-OH (85 mg, 0.20 mmol, 0.1 M final concentration) and N-hydroxysuccinimide (30 mg, 0.26 mmol) in 1.9 mL of CH2Cl2. The reaction suspension was stirred. Petition 870260086668, dated 08 / 25 / 2026, pp. 79 / 110 69 / 71 at room temperature and monitored by HPLC C18 (ELSD). After 1 h, the reaction mixture was filtered through a cotton buffer, the filtrate was loaded onto a 4 g SiliaSep column. The product was eluted with a stepwise gradient of acetone in hexane (0%, 20%, 30%, 40%, 50%, 60%, 70%; 25 mL each). Fractions containing the cleared product were combined and concentrated to give the title compound (74 mg, 0.14 mmol, 70% yield) as a cloudy film. The product was then dissolved in 1.4 mL of MeCN and stored at -20°C. HPLC C18, purity was determined by ELSD: 92.7% (RV = 10.00 mL). The predominant impurity was a hydrolysis product (7.3% @ 9.42 mL RV), possibly generated during HPLC chromatography.

[167] Step 3. 3'-{N-[4-Azido-3,3-dimethyl-1-(4-chlorophenyl)sulfonyl-2-butyloxycarbonyl]-Gly-aminoalkyl}-CpG5'. In a 15 mL Falcon tube, a 0.78 mM solution of CpG-3'NH2 (900 pL, 0.70 pmol, 0.5 mM final concentration) in 0.11 M HEPES pH 7.65 at 22°C was diluted with 340 pL of 0.11 M HEPES (100 mM final HEPES, pH 7.4 at 37°C). The solution was heated in a water bath at 37°C for 30 min and then treated with a 100 mM solution of N-[4-azido-3,3-dimethyl-1-(4-chlorophenyl)sulfonyl-2-butyloxycarbonyl]-Gly-OSu (140 pL, 14 pmol, 10 mM final concentration) in DMF. The reaction was maintained at 37°C and monitored periodically by HPLC C18. The starting material was converted to a single product peak at ~90% within 30 min. The reaction was diluted to 10 mL with Milli-Q water, and 2.5 mL of the solution were loaded into each of four NAP-25 columns.The oligonucleotide was eluted from each column with 3.5 mL of Milli-Q water, according to the manufacturer's protocol, and the eluates were combined to provide a 45 pM total oligonucleotide solution (14.0 mL, 0.63 pmol total oligo; 91% ligand-oligo by HPLC C18) as judged by A260h2o [concentration = 0.65 / (290300)*100 / 5]. The oligo solution was then concentrated to 1.4 mL using two spin filters. Petition 870260086668, dated 08 / 25 / 2026, pages 80 / 110 70 / 71 kDa Amicon Ultra-4, to provide a solution containing 0.44 mM total oligonucleotide (1.4 mL, 0.62 μmol total oligo) as judged by A260h2o [concentration = 0.64 / (290300)*1000 / 5]. HPLC C18 purity was determined at 260 nm: 90.9% (RV = 5.98 mL). Mav, 10284 (calculated); observed, 10282 Da (ESI).

[168] The corresponding oligonucleotide ligands in which R1= methylsulfonyl and R1= phenylsulfonyl were prepared in a similar manner. Example 20 Preparation of ligand-conjugated oligonucleotides

[169] 3f-[4-branched-PEG40küa-BCN / N3-(GDM 4-ClPhSO2)-Gly-aminoalkyl]-CpG-5', 134BH32. In a 1.5 mL screw-capped Eppendorf tube, a solution of 3'-{N-[4-azido-3,3-dimethyl-1(4-chlorophenyl)-sulfonyl-2-butyloxycarbonyl]-Gly-aminoalkyl}CpG-5' (0.44 mM total oligo, 1.00 mL, 0.44 μmol total oligo) was diluted with 121 μL of 0.3 M MES buffer, pH 6.0 (30 mM final buffer concentration). Next, a 5 mM solution of 4-branched-PEG40kDa-BCN (88 pL, 0.44 pmol, 0.36 mM final concentration) in MeCN was added. The reaction was maintained at room temperature and monitored by HPLC C18. The starting material was converted into a single peak of slower-eluting product. After 18 h, the reaction mixture contained ~60% product. The reaction tube was placed in a heating block at 32°C and stirred for 24 h, after which the reaction mixture contained ~67% product.The mixture was loaded onto a Phenomenex Jupiter C18 preparatory column (150 x 21.2 mm), and the product was eluted with 20%–95% MeCN in 50 mM Et3N*HOAc, pH 7.0 for 20 min (8 mL / min). Fractions containing clean product were combined, and MeCN was removed by rotary evaporation to provide an aqueous solution containing 14 pM total oligosaccharide (15 mL, 0.21 pmol) as judged by A260h2o [concentration = . Petition 870260086668, dated 08 / 25 / 2026, pp. 81 / 110 71 / 71 [0.80 / 290300) / path 0.2 cm]. The aqueous solution was further concentrated using two 10 kDa Amicon Ultra-15 spin filters to provide a solution containing 0.18 mM total oligonucleotide (1.4 mL, 0.25 pmol, 71% yield) as judged by A260h2o [concentration = 0.26 / (290300)*1000 / 5]. HPLC C18 purity was determined at 260 nm: 97.2% (RV = 8.26 mL). Example 21 Oligonucleotide release kinetics from conjugates

[170] In 1.5 mL glass HPLC vials with duplicate septum stoppers, 800 μL of 125 mM borate buffer (pH 9.0 at 37°C), and 182 μL of H2O were heated in an autosampler at 37°C for > 30 min. An aqueous solution of the conjugate from example 19 in which R1= (4-chlorophenyl)sulfonyl (110 μM total oligo, 18 pL, 2 μM total final oligo concentration) was added to each, and the cleavage reactions were periodically monitored by HPLC C18. Product formation, peak area HPLC CpG-3'-NH2 (260 nm) as a fraction of the total area of ​​260 nm, was plotted against time, giving an average t1 / 2 = 1.2 h, which extrapolates to 48 ha pH 7.4.

[171] All references described here are incorporated by reference in their entirety. Petition 870260086668, dated 08 / 25 / 2026, page 82 / 110

Claims

1 / 4 CLAIMS 1. Hydrogel derived from crosslinking units, characterized in that it has formula (IV), and drug-linker units of formula (II) Γ Γ H<í—F2 íi Z---(CH^n----c---c---O---C---Ύ---□ Fl·1 H wherein: r is an integer from 2 to 8; P1 and P2 are independently pegylated polymers with r-shaped arms of molecular weight from 1 to 40 kDa; n' is an integer from 0 to 6; R1' is -CN, -SO2N(CH3)2, -SO2CH3, -SO2Ph, -SO2PhCi, SO2N (CH2CH2) 2O, -SO2CH (CH3) 2, -SO2N (CH3) (CH2CH3) , or SO2N (CH2CH2OCH3) 2; R2' is H; each R4 is independently C1-C3 alkyl or the two R4s are taken together with the carbon atom to which they attach to form a 3- to 6-membered ring; Z*' is a connecting moiety comprising an amide, a 1,2,3-triazole, an oxime, a thioether, a thioether or an ether;(CH2)yB (CH2)x ----C----(CH2)zC' W is H , where each of x, y, and z is Petition 870260104287, dated 09 / 10 / 2026, p. 7 / 15 2 / 4 independently an integer from 0 to 6, C* is a carboxamide, thioether, thiosuccinimidyl, triazole, or oxime group, and B is -NH2, -ONH2, ketone, aldehyde, -SH, -OH, -CO2H, carboxamide group, or a group comprising a cyclooctine or bicyclononin; R1 is -CN, -SO2N(CH3)2, -SO2CH3, -SO2Ph, -SO2PhCl, SO2N(CH2CH2)2O, -SO2CH(CH3)2, -SO2N(CH3)(CH2CH3), or SO2N(CH2CH2OCH3)2; R2 is H; each R* 4 5 is independently C1-C3 alkyl or the two R4 are taken together with the carbon atom to which they attach to form a 3- to 6-membered ring;Z is a functional group for connecting drug-linking units of formula (II) to functional group B of crosslinking units of formula (IV), wherein Z is selected from the group consisting of amine, aminooxy, ketone, aldehyde, maleimidyl, thiol, alcohol, azide, 1,2,4,6-tetrazinyl, trans-cyclooctenyl, bicyclononinyl and cyclooctinyl; D is a drug; and Y is absent when D is a drug connected via an amine, or Y is -N(R6)CH2- when D is a drug connected via a phenol, alcohol, thiol, thiophenol, imidazole or non-basic amine, wherein R6 is an optionally substituted C1-C6 alkyl, an optionally substituted aryl or an optionally substituted heteroaryl.

2. Hydrogel, according to claim 1, characterized in that Y is absent.

3. Hydrogel, according to claim 1 or 2, characterized in that the drug (D) is a peptide drug.

4. Hydrogel, according to claim 3, characterized in that D is exenatide[N28Q].

5. Hydrogel, according to any of the claims in Petition 870260104287, dated 09 / 10 / 2026, page 8 / 15 3 / 4 1 to 4, characterized in that each R4 is independently C1-C3 alkyl.

6. Hydrogel, according to any one of claims 1 to 4, characterized in that each R4 is methyl.

7. Hydrogel, according to any one of claims 1 to 6, characterized in that n is an integer from 1 to 3.

8. Hydrogel, according to claim 7, characterized in that n is 1.

9. Hydrogel, according to any one of claims 1 to 8, characterized in that r is 4.

10. Drug-ligand, characterized in that it has formula (II), Γ Γ H<í—RE z--(Chyn--ç—c—o—c—y—□ R·1 H (II), wherein: n is an integer from 0 to 6; R1 is -CN, -SO2N(CH3)2, -SO2CH3, -SO2Ph, -SO2PhCl, SO2N (CH2CH2) 2O, -SO2CH (CH3) 2, -SO2N (CH3) (CH2CH3) , or SO2N (CH2CH2OCH3) 2; R2 is H; each R4 is independently C1-C3 alkyl; Z is a functional group for connecting the drug-ligand to a macromolecular carrier, wherein Z is selected from the group consisting of amine, aminooxy, ketone, aldehyde, maleimidyl, thiol, alcohol, azide, 1,2,4,6-tetrazinyl, transcyclooctenyl, bicyclononinyl and cyclooctinyl, D is a drug; and Y is absent when D is a drug connected via an amine, or Y is -N(R6)CH2- when D is a drug connected Petition 870260104287, dated 09 / 10 / 2026, page 9 / 15 4 / 4 via a phenol, alcohol, thiol, thiophenol, imidazole or non-basic amine, wherein R6 is C1-C6 alkyl, aryl or heteroaryl.

11. A drug-ligand, according to claim 10, characterized in that D is a peptide drug.

12. Drug-ligand, according to claim 11, characterized in that D is exenatide[N28Q].

13. Drug-ligand, according to any one of claims 10 to 12, characterized in that each R4 is independently C1-C3 alkyl.

14. Drug-ligand, according to claim 13, characterized in that R4 is methyl.

15. Hydrogel, characterized in that it is produced by the reaction of drug-ligands, as defined in any one of claims 10 to 14, with a macromolecular carrier. Petition 870260104287, dated 09 / 10 / 2026, page 10 / 15